

# Clinical classification of cases of toxic epidermal necrolysis and erythema multiforme

Archives of Dermatology

129, 92-96

DOI: 10.1001/archderm.129.1.92

Citation Report

#	ARTICLE	IF	CITATIONS
1	Vesiculobullous drug eruptions in children. Clinics in Dermatology, 1993, 11, 551-555.	1.6	5
2	Discovering vesiculobullous drug eruptions through dermatopathologic techniques. Clinics in Dermatology, 1993, 11, 557-565.	1.6	2
3	Drug-induced toxic epidermal necrolysis. II. Current aspects. Clinics in Dermatology, 1993, 11, 493-500.	1.6	27
4	Epidemiologic Approaches to the Study of Toxic Epidermal Necrolysis.. Journal of Investigative Dermatology, 1994, 102, 31S-33S.	0.7	21
5	Sudden death in Stevens-Johnson syndrome: a case report. Forensic Science International, 1994, 67, 197-203.	2.2	3
6	Stevens-Johnson syndrome after terbinafine therapy. Journal of the American Academy of Dermatology, 1994, 30, 509.	1.2	47
7	HLA and classic Kaposi's sarcoma in Sardinia. Journal of the American Academy of Dermatology, 1994, 30, 508-509.	1.2	1
8	Severe Adverse Cutaneous Reactions to Drugs. New England Journal of Medicine, 1994, 331, 1272-1285.	27.0	1,509
9	What is Going on in Erythema multiforme?. Dermatology, 1994, 188, 249-250.	2.1	20
10	An Autopsy Case of Malignant Lymphoma with Lyell's Syndrome. Journal of Dermatology, 1995, 22, 594-599.	1.2	8
11	Immunopathology of Stevens-Johnson Syndrome. Allergy and Asthma Proceedings, 1995, 16, 163-164.	2.2	7
12	Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. European Journal of Clinical Microbiology and Infectious Diseases, 1995, 14, 558-559.	2.9	74
13	Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): Evaluation for drug risk based on sale numbers in defined daily doses (DDD). Example of the H2-antagonists. Pharmacoepidemiology and Drug Safety, 1995, 4, 207-212.	1.9	1
14	Oral terbinafine and erythema multiforme. Clinical and Experimental Dermatology, 1995, 20, 247-248.	1.3	66
15	Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis*. Experimental Dermatology, 1995, 4, 313-316.	2.9	60
16	Erythema Multiforme With Mucous Membrane Involvement and Stevens-Johnson Syndrome Are Clinically Different Disorders With Distinct Causes. Archives of Dermatology, 1995, 131, 539.	1.4	235
17	Clinicopathologic Correlation in Erythema Multiforme and Stevens-Johnson Syndrome. Archives of Dermatology, 1995, 131, 1268.	1.4	78
18	Characteristics of Toxic Epidermal Necrolysis in Patients Undergoing Long-term Glucocorticoid Therapy. Archives of Dermatology, 1995, 131, 669.	1.4	45

#	ARTICLE	IF	CITATIONS
20	Metabolic Predisposition to Cutaneous Adverse Drug Reactions. Archives of Dermatology, 1995, 131, 544.	1.4	114
22	An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. Journal of Clinical Epidemiology, 1995, 48, 1099-1108.	5.0	70
24	Medication Use and the Risk of Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. New England Journal of Medicine, 1995, 333, 1600-1608.	27.0	1,320
25	Toxic epidermal necrolysis in a burns centre: A 6-year review. Burns, 1996, 22, 275-278.	1.9	83
26	Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): Structure and results of a population-based registry. Journal of Clinical Epidemiology, 1996, 49, 769-773.	5.0	327
27	l'erythème polymorphe et syndrome de Stevens-Johnson sont deux maladies différentes. Revue De Médecine Interne, 1996, 17, 383s.	1.0	0
29	TOXIC EPIDERMAL NECROLYSIS. International Journal of Dermatology, 1996, 35, 523-527.	1.0	27
30	Toxic epidermal necrolysis. Australasian Journal of Dermatology, 1996, 37, 167-177.	0.7	7
31	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Are Severity Variants of the Same Disease which Differs from Erythema Multiforme. Journal of Dermatology, 1997, 24, 726-729.	1.2	154
32	Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children. European Journal of Pediatrics, 1997, 156, 90-93.	2.7	96
33	Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Medicine, 1997, 23, 1237-44.	8.2	163
34	European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study. European Journal of Clinical Pharmacology, 1998, 53, 299-302.	1.9	17
35	HLA genotype and increased risk of skin cancer. British Journal of Dermatology, 1998, 139, 1111-1111.	1.5	3
36	Chronic actinic dermatitis occurring in young patients with atopic dermatitis. British Journal of Dermatology, 1998, 139, 1112-1113.	1.5	27
37	Papuloerythroderma associated with hepatocellular carcinoma. British Journal of Dermatology, 1998, 139, 1115-1116.	1.5	23
38	Familial naevus sebaceous of Jadassohn. British Journal of Dermatology, 1998, 139, 1119-1120.	1.5	15
39	Leg ulcer associated with hydroxyurea treatment in a patient with chronic myelogenous leukaemia: successful treatment with prostaglandin E1 and pentoxifylline. British Journal of Dermatology, 1998, 139, 1124-1126.	1.5	23
40	Severe, refractory epidermolysis bullosa acquisita complicated by an oesophageal stricture responding to intravenous immune globulin. British Journal of Dermatology, 1998, 139, 1126-1127.	1.5	40

#	ARTICLE	IF	CITATIONS
41	Severe bullous drug reactions treated successfully with cyclophosphamide. British Journal of Dermatology, 1998, 139, 1127-1128.	1.5	21
42	Bullous fixed drug eruption due to paracetamol with an unusual immunofluorescence pattern. British Journal of Dermatology, 1998, 139, 1129-1131.	1.5	16
43	Pseudoporphyria induced by mefenamic acid. British Journal of Dermatology, 1998, 139, 1131-1132.	1.5	20
44	Terbinafine-induced subacute cutaneous lupus erythematosus. British Journal of Dermatology, 1998, 139, 1132-1133.	1.5	48
45	Exacerbation of systemic lupus erythematosus induced by terbinafine. British Journal of Dermatology, 1998, 139, 1133-1133.	1.5	32
46	Onychomycosis caused by infection with Paecilomyces lilacinus. British Journal of Dermatology, 1998, 139, 1133-1135.	1.5	17
47	A solitary collagenoma presenting in the labium majus. British Journal of Dermatology, 1998, 139, 1135-1136.	1.5	21
48	Gelatinases in drug-induced toxic epidermal necrolysis. European Journal of Clinical Investigation, 1998, 28, 528-532.	3.4	24
49	Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet, The, 1998, 352, 1586-1589.	13.7	414
50	The histopathology of drug rashes. Current Diagnostic Pathology, 1998, 5, 138-149.	0.4	5
51	Drug-Induced Toxic Epidermal Necrolysis. Clinics in Dermatology, 1998, 16, 399-408.	1.6	56
52	Soluble fractions of tumor necrosis factor-alpha, interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with second-degree burns.. International Journal of Molecular Medicine, 1998, 1, 459-62.	4.0	24
53	Toxic Epidermal Necrolysis Syndrome: Mortality Rate Reduced with Early Referral to Regional Burn Center. Plastic and Reconstructive Surgery, 1998, 102, 1018-1022.	1.4	128
54	Stevensjohnson Syndrome Caused by a Health Drink (Eberu®) Containing Ophiopogonis Tuber. Journal of Dermatology, 1998, 25, 662-665.	1.2	25
56	Clinical and Immunological Characteristics of Oculomucocutaneous Disorders. , 1999, 30, 62-83.		1
57	Stevens-Johnson Syndrome in Patients on Phenytoin and Cranial Radiotherapy. Acta OncolÃ³gica, 1999, 38, 111-116.	1.8	47
58	Photodynamic Therapy of Recalcitrant Warts with 5-Aminolevulinic Acid: A Retrospective Analysis. Acta Dermato-Venereologica, 1999, 79, 400-401.	1.3	18
59	Stevens-Johnson Syndrome after Sertraline. Acta Dermato-Venereologica, 1999, 79, 401-401.	1.3	22

#	ARTICLE	IF	CITATIONS
60	Erythema Multiforme Secondary to Amoxicillin/Clavulanic Acid Exposure. <i>Annals of Pharmacotherapy</i> , 1999, 33, 109-110.	1.9	3
61	Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 839-846.	2.4	140
62	Evidence for a single genetic locus in Clouston's hidrotic ectodermal dysplasia. <i>British Journal of Dermatology</i> , 1999, 140, 963-964.	1.5	23
63	Linear IgA disease with circulating IgA antibodies against the NC16A domain of BP180. <i>British Journal of Dermatology</i> , 1999, 140, 964-966.	1.5	20
64	Circulating activation markers of severe atopic dermatitis following ultraviolet A1 cold light phototherapy: eosinophil cationic protein, soluble interleukin-2 receptor and soluble interleukin-4 receptor. <i>British Journal of Dermatology</i> , 1999, 140, 966-968.	1.5	18
65	Maffucci's syndrome with oral and intestinal haemangioma. <i>British Journal of Dermatology</i> , 1999, 140, 968-969.	1.5	24
66	An oculocutaneous presentation of essential progressive telangiectasia. <i>British Journal of Dermatology</i> , 1999, 140, 969-971.	1.5	7
67	Urticaria pigmentosa occurring with juvenile xanthogranuloma. <i>British Journal of Dermatology</i> , 1999, 140, 990-991.	1.5	14
68	Primary cutaneous CD30 (Ki-1)-positive anaplastic large cell lymphoma associated with renal cell carcinoma. <i>British Journal of Dermatology</i> , 1999, 140, 971-972.	1.5	6
69	Dramatic postcoital vulval laceration and bruising in Ehlers-Danlos syndrome. <i>British Journal of Dermatology</i> , 1999, 140, 974-974.	1.5	2
70	Pitted keratolysis of the palm arising after herpes zoster. <i>British Journal of Dermatology</i> , 1999, 140, 974-975.	1.5	7
71	Tufted folliculitis in a 10-year-old child. <i>British Journal of Dermatology</i> , 1999, 140, 975-976.	1.5	1
72	Do mucin-phagocytosing histiocytes in localized lipoatrophy have any primary pathogenetic importance?. <i>British Journal of Dermatology</i> , 1999, 140, 976-978.	1.5	6
73	The seborrhoeic pattern of dermatomyositis. <i>British Journal of Dermatology</i> , 1999, 140, 978-979.	1.5	9
74	Cetirizine-induced urticarial reaction. <i>British Journal of Dermatology</i> , 1999, 140, 979-980.	1.5	31
75	Nevirapine-induced overlap Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>British Journal of Dermatology</i> , 1999, 140, 980-982.	1.5	24
76	Psoriasiform drug eruption induced by fluorescein sodium used for fluorescein angiography. <i>British Journal of Dermatology</i> , 1999, 140, 982-984.	1.5	7
77	The response of rosacea to eradication of <i>Helicobacter pylori</i> . <i>British Journal of Dermatology</i> , 1999, 140, 984-985.	1.5	30

#	ARTICLE	IF	CITATIONS
78	Minocycline for the treatment of cutaneous silicone granulomas. British Journal of Dermatology, 1999, 140, 985-987.	1.5	77
79	Bowen's disease of the leg treated with weekly pulses of 5% fluorouracil cream. British Journal of Dermatology, 1999, 140, 987-988.	1.5	25
80	The time course of phototoxicity of topical PUVA: 8-methoxypsoralen cream-PUVA vs. 8-methoxypsoralen gel-PUVA. British Journal of Dermatology, 1999, 140, 988-990.	1.5	24
81	Cutaneous T-cell lymphoma occurring with intestinal B-cell lymphoma. British Journal of Dermatology, 1999, 140, 972-973.	1.5	6
83	The diagnostic role of the in vitro drug-induced interferon-gamma release test in Stevens-Johnson syndrome. International Journal of Dermatology, 1999, 38, 835-840.	1.0	20
84	Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Australasian Journal of Dermatology, 1999, 40, 153-157.	0.7	52
85	Lamotrigine. Epilepsia, 1999, 40, s30-s36.	5.1	65
86	Epidermal calprotectin in drug-induced toxic epidermal necrolysis. Journal of Cutaneous Pathology, 1999, 26, 301-305.	1.3	20
89	Allergic emergencies encountered by the dermatologist. Clinical Reviews in Allergy and Immunology, 1999, 17, 497-511.	6.5	5
90	Increased Risk of Erythema Multiforme Major with Combination Anticonvulsant and Radiation Therapies. Pharmacotherapy, 1999, 19, 223-227.	2.6	61
91	Anticonvulsant-Induced Cutaneous Reactions. CNS Drugs, 1999, 12, 215-236.	5.9	19
92	Treatment of Severe Drug Eruptions. Journal of Dermatology, 1999, 26, 718-722.	1.2	75
93	Stevens-Johnson Syndrome in India – Risk Factors, Ocular Manifestations and Management. Ophthalmologica, 2000, 214, 285-288.	1.9	23
94	Cocaine-Related Stevens-Johnson Syndrome. Dermatology, 2000, 201, 258-260.	2.1	30
95	Management of Drug-Induced Toxic Epidermal Necrolysis. Journal of Cutaneous Medicine and Surgery, 2000, 4, 96-102.	1.2	12
96	A Case of Toxic Epidermal Necrolysis – Type Drug Eruption Induced by Oral Lysozyme Chloride. Journal of Dermatology, 2000, 27, 401-404.	1.2	6
97	Immunoregulatory Effector Cells in Drug-Induced Toxic Epidermal Necrolysis. American Journal of Dermatopathology, 2000, 22, 413-417.	0.6	78
98	An Unusual Form of Stevens-Johnson Syndrome with Subcorneal Pustules Associated with Mycoplasma pneumoniae Infection. Pediatric Dermatology, 2000, 17, 202-204.	0.9	19

#	ARTICLE	IF	CITATIONS
99	Toxic epidermal necrolysis in Western Australia. Australasian Journal of Dermatology, 2000, 41, 31-33.	0.7	24
100	Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Archives of Disease in Childhood, 2000, 83, 347-352.	1.9	203
101	Parvovirus Infection of Keratinocytes as a Cause of Canine Erythema Multiforme. Veterinary Pathology, 2000, 37, 647-649.	1.7	39
102	Corticosteroid Therapy in an Additional 13 Cases of Stevens-Johnson Syndrome: A Total Series of 67 Cases. Allergy and Asthma Proceedings, 2000, 21, 101-105.	2.2	87
103	Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome. Archives of Dermatology, 2000, 136, 323-7.	1.4	399
104	Prospects for Control of Herpes Simplex Virus Disease through Immunization. Clinical Infectious Diseases, 2000, 30, 549-566.	5.8	176
105	Improving the Outcome of Patients With Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome. Archives of Dermatology, 2000, 136, 410-1.	1.4	34
106	Drug eruptions. Current Problems in Dermatology, 2000, 12, 58-62.	0.0	4
107	Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet, The, 2000, 356, 1587-1591.	13.7	316
108	Drug-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. American Journal of Clinical Dermatology, 2000, 1, 349-360.	6.7	140
109	TOXIC EPIDERMAL NECROLYSIS. Dermatologic Clinics, 2000, 18, 485-495.	1.7	53
110	NEW ADVANCES IN SEVERE ADVERSE DRUG REACTIONS. Dermatologic Clinics, 2001, 19, 697-709.	1.7	25
111	Quand la peau suscite l'urgence. Revue Francaise D'allergologie Et D'immunologie Clinique, 2001, 41, 331-335.	0.1	1
112	Síndrome de Stevens-Johnson/necrólisis epidérmica tóxica. Piel, 2001, 16, 444-457.	0.0	10
113	Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. Aids, 2001, 15, 1843-1848.	2.2	178
114	Intravenous Immunoglobulin Therapy for Stevens-Johnson Syndrome. Southern Medical Journal, 2001, 94, 342-343.	0.7	8
115	Erythema multiforme Associated with Cytomegalovirus Infection in Nonimmunosuppressed Patients. Dermatology, 2001, 203, 299-302.	2.1	28
116	Stevens-Johnson Syndrome in a Patient Receiving Anticonvulsant Therapy During Cranial Irradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2001, 24, 347-350.	1.3	29

#	ARTICLE	IF	CITATIONS
117	Drug eruptions in children. Current Problems in Pediatrics, 2001, 31, 207-234.	1.1	43
118	Toxic Epidermal Necrolysis Induced by Nevirapine Therapy: Description of Two Cases and Review of the Literature. Journal of Infection, 2001, 43, 246-249.	3.3	20
119	Life-threatening adverse events of antiepileptic drugs. Epilepsy Research, 2001, 47, 155-174.	1.6	68
120	Acetylsalicylic acid and other salicylates in relation to Stevensâ€Johnson syndrome and toxic epidermal necrolysis. British Journal of Clinical Pharmacology, 2001, 51, 174-176.	2.4	8
121	Trimethoprim/Sulfamethoxazoleâ€Induced Toxic Epidermal Necrolysis. Annals of Pharmacotherapy, 2001, 35, 694-697.	1.9	24
122	Toxic Epidermal Necrolysis Treated with Intravenous High-Dose Immunoglobulins: Our Experience. Dermatology, 2001, 203, 45-49.	2.1	105
124	Soluble Interleukin 2 Receptor and Interleukin 1Î± in Toxic Epidermal Necrolysis. Archives of Dermatology, 2002, 138, 29-32.	1.4	41
125	Correlations Between Clinical Patterns and Causes of Erythema Multiforme Majus, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis. Archives of Dermatology, 2002, 138, 1019-24.	1.4	510
126	Needle Aspiration to Determine Cause of Pneumonia. AAP Grand Rounds, 2002, 7, 53-54.	0.0	0
127	Outcome of Patients with Toxic Epidermal Necrolysis Syndrome Revisited. Plastic and Reconstructive Surgery, 2002, 110, 768-773.	1.4	70
128	Toxic Epidermal Necrolysis After Phenytoin Usage in a Brain Trauma Patient. Journal of Neurosurgical Anesthesiology, 2002, 14, 229-233.	1.2	1
129	Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children. Drug Safety, 2002, 25, 965-972.	3.2	170
130	Drug eruptions in children. Current Problems in Dermatology, 2002, 14, 153-182.	0.0	3
131	Increased interleukin 10, tumor necrosis factor Î±, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. Journal of the American Academy of Dermatology, 2002, 47, 58-62.	1.2	78
132	Drug Eruptions and Other Adverse Drug Effects in Aged Skin. Clinics in Geriatric Medicine, 2002, 18, 21-42.	2.6	30
133	AlteraciÃ³n pulmonar y renal en sÃndrome Stevens-Johnson de evoluciÃ³n fatal. Estudio anatomopatolÃ³gico. Anales De PediatrÃa, 2002, 57, 71-73.	0.2	3
134	Dermatological ADRs. , 0, , 423-433.		0
135	A Case Report and a Proposed Algorithm for the Transfer of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis to a Burn Center. Military Medicine, 2002, 167, 701-704.	0.8	14



#	ARTICLE	IF	CITATIONS
136	Erythema multiforme due to Rofecoxib. <i>Dermatology</i> , 2002, 204, 304-305.	2.1	16
138	Treatment of erythema multiforme, Stevens-Johnson Syndrome, and toxic epidermal necrolysis. <i>Dermatologic Therapy</i> , 2002, 15, 397-408.	1.7	9
139	Toxic epidermal necrolysis in a pregnant, HIV-infected woman. <i>International Journal of Dermatology</i> , 2002, 41, 600-601.	1.0	13
140	Treatment of Toxic Epidermal Necrolysis With Moisture-Retentive Ointment: A Case Report and Review of the Literature. <i>Dermatologic Surgery</i> , 2003, 29, 185-188.	0.8	23
141	Tolerability and Pharmacokinetics of Oral Loading with Lamotrigine in Epilepsy Monitoring Units. <i>Epilepsia</i> , 2003, 44, 536-539.	5.1	18
142	Oral manifestations of erythema multiforme. <i>Dermatologic Clinics</i> , 2003, 21, 195-205.	1.7	154
143	Dos casos de necrólisis epidérmica tóxica localizada asociada a radioterapia. <i>Actas Dermo-sifiligráficas</i> , 2003, 94, 475-478.	0.4	5
144	Photo-Induced Stevens-Johnson Syndrome Due to Sulfasalazine Therapy. <i>Annals of Pharmacotherapy</i> , 2003, 37, 1241-1243.	1.9	15
145	Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Are Induced by Soluble Fas Ligand. <i>American Journal of Pathology</i> , 2003, 162, 1515-1520.	3.8	560
146	Drug allergy in a general hospital: results of a novel prospective inpatient reporting system. <i>Annals of Allergy, Asthma and Immunology</i> , 2003, 90, 342-347.	1.0	98
147	Progress in the Understanding of the Pathology and Pathogenesis of Cutaneous Drug Eruptions. <i>American Journal of Clinical Dermatology</i> , 2003, 4, 407-428.	6.7	67
148	Stevens-Johnson Syndrome Associated with Malarone Antimalarial Prophylaxis. <i>Clinical Infectious Diseases</i> , 2003, 37, e5-e7.	5.8	24
149	Treatment of Toxic Epidermal Necrolysis With High-Dose Intravenous Immunoglobulins. <i>Archives of Dermatology</i> , 2003, 139, 26.	1.4	625
150	Possible Cefotaxime-Induced Stevens-Johnson Syndrome. <i>Annals of Pharmacotherapy</i> , 2003, 37, 812-814.	1.9	16
151	Case 23-2003. <i>New England Journal of Medicine</i> , 2003, 349, 382-391.	27.0	41
152	Unusual Spindle Cell Squamous Carcinoma in a Renal Transplant Patient. <i>Acta Dermato-Venereologica</i> , 2003, 84, 61-64.	1.3	9
153	Erythema multiforme-Like Drug Eruption with Oral Involvement after Intake of Leflunomide. <i>Dermatology</i> , 2003, 207, 386-389.	2.1	35
154	Dermatological and Ophthalmological Sequels in Toxic Epidermal Necrolysis. <i>Dermatology</i> , 2003, 207, 33-36.	2.1	81

#	ARTICLE	IF	CITATIONS
155	Pediatric exanthems. Clinics in Family Practice, 2003, 5, 557-588.	0.3	4
156	Treatment of Toxic Epidermal Necrolysis With Moisture-Retentive Ointment. Dermatologic Surgery, 2003, 29, 185-188.	0.8	12
157	Outbreak of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Mebendazole and Metronidazole Use Among Filipino Laborers in Taiwan. American Journal of Public Health, 2003, 93, 489-492.	2.7	45
158	Effect of High-Dose Intravenous Immunoglobulin Therapy in Stevens-Johnson Syndrome: A Retrospective, Multicenter Study. Dermatology, 2003, 207, 96-99.	2.1	82
159	Stevens- Johnson syndrome: case presentation. Journal of Clinical Pediatric Dentistry, 2003, 27, 71-76.	1.0	4
160	Toxic Epidermal Necrolysis Due to Administration of Celecoxib (Celebrex). Southern Medical Journal, 2003, 96, 320-321.	0.7	6
161	Severe Cutaneous Reactions Associated with the Use of Human Immunodeficiency Virus Medications. Acta Dermato-Venereologica, 2003, 83, 1-9.	1.3	89
162	Early Cyclosporine Treatment of Incipient Toxic Epidermal Necrolysis Induced by Concomitant Use of Lamotrigine and Sodium Valproate. Acta Dermato-Venereologica, 2003, 84, 90-91.	1.3	22
163	Spectrum of Anticonvulsant Hypersensitivity Syndrome: Controversy of Treatment. Journal of Child Neurology, 2004, 19, 619-623.	1.4	6
164	Toxic Epidermal Necrolysis after Cranial Radiotherapy and Phenytoin Treatment. Oncology Research and Treatment, 2004, 27, 389-392.	1.2	11
165	Erythema multiforme associated with phenytoin and cranial radiation therapy: A report of three patients and review of the literature. International Journal of Dermatology, 2004, 43, 67-73.	1.0	71
166	Acetaminophen-Induced Toxic Epidermal Necrolysis in a Child. Pediatric Dermatology, 2004, 21, 236-238.	0.9	19
167	Toxic Epidermal Necrolysis in Patients Receiving Anticonvulsants and Cranial Irradiation: A Risk to Consider. Journal of Neuro-Oncology, 2004, 66, 345-350.	2.9	70
168	Possible involvement of gelatinase A (MMP2) and gelatinase B (MMP9) in toxic epidermal necrolysis or Stevens-Johnson syndrome. Archives of Dermatological Research, 2004, 296, 220-225.	1.9	23
169	Assessment and management of cutaneous reactions with amifostine administration: Findings of the ethylol (amifostine) cutaneous treatment advisory panel (ECTAP). International Journal of Radiation Oncology Biology Physics, 2004, 60, 302-309.	0.8	28
170	Toxicodermias inmunológicas en pacientes inmunocompetentes. EMC - Dermatología, 2004, 38, 1-8.	0.1	0
171	Stevens-Johnson Syndrome After Immunization With Smallpox, Anthrax, and Tetanus Vaccines. Mayo Clinic Proceedings, 2004, 79, 1193-1196.	3.0	13
173	ADVERSE REACTIONS OF NITROFURANTOIN, TRIMETHOPRIM AND SULFAMETHOXAZOLE IN CHILDREN. Journal of Urology, 2004, 172, 448-453.	0.4	103

#	ARTICLE	IF	CITATIONS
174	Esophageal stricture as a late sequel of Stevens-Johnson syndrome in adults: incidental detection because of foreign body impaction. <i>Gastrointestinal Endoscopy</i> , 2004, 59, 437-440.	1.0	13
175	Diabetic ketoacidosis in a patient with chronic calcific pancreatitis after minor papilla stent insertion. <i>Gastrointestinal Endoscopy</i> , 2004, 59, 440-443.	1.0	1
176	Stevens-Johnson Syndrome After Immunization With Smallpox, Anthrax, and Tetanus Vaccines. <i>Mayo Clinic Proceedings</i> , 2004, 79, 1193-1196.	3.0	23
177	Intravenous Immunoglobulin for Treatment of Toxic Epidermal Necrolysis. <i>American Journal of the Medical Sciences</i> , 2005, 329, 95-98.	1.1	12
178	Review of common cutaneous adverse drug reactions. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2005, 47, 27-29.	0.6	0
179	Targeting the "Target Lesions". <i>Skinmed</i> , 2005, 4, 311-312.	0.0	4
180	High-Dose Intravenous Immunoglobulins in the Treatment of Toxic Epidermal Necrolysis: An Asian Series. <i>Journal of Dermatology</i> , 2005, 32, 1-6.	1.2	52
181	Heterotopic Ossification Related to Toxic Epidermal Necrolysis in a Patient with Behçet's Disease. <i>Journal of Dermatology</i> , 2005, 32, 469-473.	1.2	7
182	Number IV Erythema multiforme. <i>Oral Diseases</i> , 2005, 11, 261-267.	3.0	103
183	Lyell syndrome revisited: analysis of 18 cases of severe bullous skin disease in a burns unit. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2005, 58, 73-80.	1.1	16
184	Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2005, 58, 504-510.	1.1	67
186	Clinical heterogeneity of drug hypersensitivity. <i>Toxicology</i> , 2005, 209, 123-129.	4.2	379
187	Naproxen sodium-induced toxic epidermal necrolysis: a case report and review of the literature. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2005, 37, 343-347.	0.7	3
188	Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. <i>Archives of Dermatological Research</i> , 2005, 297, 266-273.	1.9	24
189	Uncovering Histologic Criteria With Prognostic Significance in Toxic Epidermal Necrolysis. <i>Archives of Dermatology</i> , 2005, 141, 683-7.	1.4	75
190	Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. <i>Neurology</i> , 2005, 64, 1134-1138.	1.1	293
191	Cell-Mediated Immunologic Mechanism and Severity of TEN. <i>Archives of Dermatology</i> , 2005, 141, 775-6.	1.4	14
192	Toxic epidermal necrolysis (TEN) Lyell's syndrome. <i>Journal of Dermatological Treatment</i> , 2005, 16, 278-286.	2.2	26

#	ARTICLE	IF	CITATIONS
193	Delayed-Type Hypersensitivity. , 2005, , 192-194.		0
194	MRI of segmental zoster paresis. Neurology, 2005, 64, 1138-1138.	1.1	12
195	www.archdermatol.com Communicates With the International Dermatology Community. Archives of Dermatology, 2005, 141, 505-6.	1.4	2
198	Case 34-2005. New England Journal of Medicine, 2005, 353, 2057-2066.	27.0	7
199	Mycoplasma pneumoniae-induced Stevens-Johnson syndrome without skin lesions: Fact or fiction?. Journal of the American Academy of Dermatology, 2005, 52, 312-315.	1.2	73
200	Erythema multiforme: a review and contrast from Stevens-Johnson syndrome/toxic epidermal necrolysis. Dental Clinics of North America, 2005, 49, 67-76.	1.8	56
201	Life-threatening acute adverse cutaneous drug reactions. Clinics in Dermatology, 2005, 23, 171-181.	1.6	152
202	Serious Drug Rashes in Children. Advances in Pediatrics, 2005, 52, 207-222.	1.4	0
203	Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Annals of Allergy, Asthma and Immunology, 2005, 94, 419-436.	1.0	271
204	Intravenous Immunoglobulin Use in Patients with Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome. American Journal of Clinical Dermatology, 2006, 7, 359-368.	6.7	50
206	Penicillins. , 2006, , 2756-2772.		0
207	Adverse Cutaneous Drug Eruptions and HIV: a Clinician's Global Perspective. Dermatologic Clinics, 2006, 24, 459-472.	1.7	35
208	36-Year-Old Man With Productive Cough and Diffuse Rash. Mayo Clinic Proceedings, 2006, 81, 945-948.	3.0	4
210	Rash and fever. Journal of Emergency Medicine, 2006, 31, 293-297.	0.7	6
211	Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: Our current understanding. International Immunopharmacology, 2006, 6, 543-549.	3.8	110
212	Toxic Epidermal Necrolysis and Intravenous Immunoglobulin: A Review. Seminars in Cutaneous Medicine and Surgery, 2006, 25, 91-93.	1.6	39
214	Síndrome de Stevens-Johnson e necrólise epidérmica tóxica em medicina intensiva. Revista Brasileira De Terapia Intensiva, 2006, 18, 292-297.	0.3	7
216	Human Herpesvirus 6 Reactivation in Trichloroethylene-exposed Workers Suffering from Generalized Skin Disorders Accompanied by Hepatic Dysfunction. Journal of Occupational Health, 2006, 48, 417-423.	2.1	52

#	ARTICLE	IF	CITATIONS
218	Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. <i>Experimental Dermatology</i> , 2006, 15, 381-386.	2.9	23
219	Erythema Multiforme due to <i>Mycoplasma pneumoniae</i> Infection in Two Children. <i>Pediatric Dermatology</i> , 2006, 23, 546-555.	0.9	82
220	The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. <i>British Journal of Dermatology</i> , 2006, 154, 319-324.	1.5	50
221	Multiple hereditary infundibulocystic basal cell carcinomas: a distinctive genodermatosis. <i>British Journal of Dermatology</i> , 2006, 154, 1007-1010.	1.5	13
222	Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. <i>British Journal of Dermatology</i> , 2006, 154, 1006-1007.	1.5	20
223	Sera from patients with toxic epidermal necrolysis contain autoantibodies to periplakin. <i>British Journal of Dermatology</i> , 2006, 155, 337-343.	1.5	16
224	Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>British Journal of Dermatology</i> , 2006, 155, 722-728.	1.5	104
225	Chronic pulmonary complications associated with toxic epidermal necrolysis: Report of a severe case with anti-Ro/SS-A and a review of the published work. <i>Journal of Dermatology</i> , 2006, 33, 616-622.	1.2	51
226	Intravenous immunoglobulin in toxic epidermal necrolysis. <i>International Journal of Dermatology</i> , 2006, 45, 1117-1118.	1.0	8
227	Erythema multiforme-like drug eruption caused by sennoside. <i>International Journal of Dermatology</i> , 2006, 45, 1123-1123.	1.0	7
228	Performance of the SCORTEN During the First Five Days of Hospitalization to Predict the Prognosis of Epidermal Necrolysis. <i>Journal of Investigative Dermatology</i> , 2006, 126, 272-276.	0.7	179
231	Treatment of Severe Adverse Cutaneous Drug Reactions With Human Intravenous Immunoglobulin in Two Dogs. <i>Journal of the American Animal Hospital Association</i> , 2006, 42, 312-320.	1.1	28
232	Drug Rash with Eosinophilia and Systemic Symptoms versus Stevens-Johnson Syndrome “a Case that Indicates a Stumbling Block in the Current Classification. <i>International Archives of Allergy and Immunology</i> , 2006, 141, 308-310.	2.1	23
233	Canadian Consensus Statement on the Use of Intravenous Immunoglobulin Therapy in Dermatology. <i>Journal of Cutaneous Medicine and Surgery</i> , 2006, 10, 205-221.	1.2	30
234	Dexamethasone Pulse Therapy for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. <i>Acta Dermato-Venereologica</i> , 2007, 87, 144-148.	1.3	181
235	“Atypical” Stevens-Johnson Syndrome?. <i>Pediatrics</i> , 2007, 120, 451-452.	2.1	9
236	Breastfeeding, Hospitalizations, and the Role of Ethnicity. <i>Pediatrics</i> , 2007, 120, 452-453.	2.1	1
237	Stevens-Johnson Syndrome, Drug-Induced Hypersensitivity Syndrome and Toxic Epidermal Necrolysis Caused by Allopurinol in Patients with a Common HLA Allele: What Causes the Diversity?. <i>Dermatology</i> , 2007, 215, 86-88.	2.1	57

#	ARTICLE	IF	CITATIONS
238	Glutathione-S-Transferase Pi Expression in Toxic Epidermal Necrolysis: A Marker of Putative Oxidative Stress in Keratinocytes. <i>Skin Pharmacology and Physiology</i> , 2007, 20, 66-70.	2.5	20
239	Serum Levels of the Th1 Promoter IL-12 and the Th2 Chemokine TARC Are Elevated in Erythema Multiforme and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Correlate with Soluble Fas Ligand Expression. <i>Dermatology</i> , 2007, 214, 296-304.	2.1	31
240	Cutaneous Adverse Reactions to Valdecoxib Distinct From Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Archives of Dermatology</i> , 2007, 143, 711-6.	1.4	33
241	“Atypical” Stevens-Johnson Syndrome?: In Reply. <i>Pediatrics</i> , 2007, 120, 452-452.	2.1	2
242	Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Pharmacogenomics</i> , 2007, 8, 1661-1691.	1.3	33
243	Epidemiology and Causes of Severe Cutaneous Adverse Reactions to Drugs. , 2007, , 18-31.		16
244	A Randomized, Double-blind, Placebo-Controlled Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis. <i>Archives of Dermatology</i> , 2007, 143, 463-70.	1.4	58
245	Management of Scalp Toxic Epidermal Necrolysis and Cranial Osteomyelitis With Serratus Anterior Myocutaneous Pedicle Flap: A Case Report. <i>Journal of Burn Care and Research</i> , 2007, 28, 524-529.	0.4	6
247	Erythema multiforme and related disorders. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2007, 103, 642-654.	1.4	78
248	Approach to the Acute, Generalized, Blistering Patient. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2007, 26, 139-146.	1.6	12
249	New Grading System for the Evaluation of Chronic Ocular Manifestations in Patients with Stevens-Johnson Syndrome. <i>Ophthalmology</i> , 2007, 114, 1294-1302.	5.2	241
250	In the pursuit of classifying severe cutaneous adverse reactions. <i>Clinics in Dermatology</i> , 2007, 25, 348-349.	1.6	24
251	Toxic epidermal necrolysis. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 181-200.	1.2	295
252	Case Report 2. Severe erythema multiforme induced by two consecutive anti-angiogenic drugs. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 30-31.	2.2	2
254	Head and Neck Manifestations of Systemic Disease. , 0, , .		3
255	Cutaneous Reactions to Drugs in Children. <i>Pediatrics</i> , 2007, 120, e1082-e1096.	2.1	94
256	Recognition and Management of Severe Cutaneous Drug Reactions. <i>Dermatologic Clinics</i> , 2007, 25, 245-253.	1.7	64
258	Apoptosis in ibuprofen-induced Stevens-Johnson syndrome. <i>Translational Research</i> , 2007, 149, 254-259.	5.0	27

#	ARTICLE	IF	CITATIONS
260	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. , 2007, , 1016-1019.		1
261	Soluble FAS Ligand: A Discriminating Feature between Drug-Induced Skin Eruptions and Viral Exanthemas. Journal of Investigative Dermatology, 2007, 127, 802-807.	0.7	61
262	Ocular manifestations and complications of Stevens?Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 527-531.	5.7	142
263	Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1439-1444.	5.7	235
264	Two case reports of oral ulcers with lamotrigine several weeks after oxcarbazepine withdrawal. Bipolar Disorders, 2007, 9, 310-313.	1.9	14
265	Toxic epidermal necrolysis in a child successfully treated with cyclosporin A and methylprednisolone. Pediatrics International, 2007, 49, 659-662.	0.5	24
266	TOXIC EPIDERMAL NECROLYSIS/STEVENS?JOHNSON SYNDROME: CURRENT TRENDS IN MANAGEMENT. ANZ Journal of Surgery, 2007, 77, 671-676.	0.7	28
267	Serum interleukin-13 levels are increased in patients with Stevensâ€Johnson syndrome/ toxic epidermal necrolysis but not in those with erythema multiforme. British Journal of Dermatology, 2007, 158, 071018053044005-???	1.5	6
268	Epidermal interleukin-8 and its receptor CXCR2 in drug-induced toxic epidermal necrolysis. Clinical and Experimental Dermatology, 2007, 32, 728-732.	1.3	15
269	Conjunctival Pigmentation in Stevens-Johnson Syndrome. Annals of Ophthalmology, 2007, 39, 152-157.	0.0	2
270	Stevens-Johnson syndrome in children receiving phenobarbital therapy and cranial radiotherapy. Journal of Neuro-Oncology, 2007, 85, 213-215.	2.9	11
271	Management of Dysphagia in Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS). Dysphagia, 2007, 22, 187-192.	1.8	20
272	Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations. European Journal of Pediatrics, 2007, 166, 585-588.	2.7	22
273	Conjunctival Pigmentation in Stevensâ€Johnson Syndrome. Comprehensive Therapy, 2007, 33, 99-103.	0.2	1
274	Erythema multiforme and Stevens-Johnson syndrome following radiotherapy. Radiation Medicine, 2007, 25, 27-30.	0.8	16
275	Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer. Breast Cancer, 2008, 15, 321-323.	2.9	9
276	Lack of evidence for erythema multiforme in skin reaction to adalimumab: Comment on the article by Beuthien et al. Arthritis and Rheumatism, 2008, 58, 1205-1206.	6.7	1
278	Stevensâ€Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study. Journal of Investigative Dermatology, 2008, 128, 35-44.	0.7	807



#	ARTICLE	IF	CITATIONS
279	Nevirapine-Induced Stevens-Johnson Syndrome in a Pediatric Patient. <i>Pediatric Dermatology</i> , 2008, 25, 128-129.	0.9	13
280	Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Autoimmunity Reviews</i> , 2008, 7, 598-605.	5.8	176
281	Carbamazepine, <i>HLA-B*1502</i> and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. <i>Pharmacogenomics</i> , 2008, 9, 1543-1546.	1.3	421
282	Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 122, 992-1000.	2.9	99
283	Energy Requirements of Pediatric Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Nutrition in Clinical Practice</i> , 2008, 23, 547-550.	2.4	40
284	Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 25-32.	1.2	393
285	Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 33-40.	1.2	423
286	Toxic epidermal necrolysis with a rare long-term oral complication requiring surgical intervention. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2008, 105, e29-e33.	1.4	23
287	Toxic epidermal necrolysis: Use of Biobrane® for skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients. <i>Burns</i> , 2008, 34, 487-492.	1.9	64
289	Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. <i>Radiotherapy and Oncology</i> , 2008, 87, 300-303.	0.6	30
290	Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 879-888.	3.0	88
291	Acute Skin Eruptions That Are Positive for Herpes Simplex Virus DNA Polymerase in Patients With Stem Cell Transplantation. <i>Archives of Dermatology</i> , 2008, 144, 902-7.	1.4	23
292	HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Pharmacogenomics</i> , 2008, 9, 1617-1622.	1.3	368
293	Management of toxic epidermal necrolysis and related syndromes. <i>Postgraduate Medical Journal</i> , 2008, 84, 60-65.	1.8	31
294	Fluconazole-induced Stevens-Johnson Syndrome in a HIV-negative Patient. <i>Acta Dermato-Venereologica</i> , 2008, 88, 521-522.	1.3	8
295	Stevens-Johnson syndrome: Pathogenesis, diagnosis, and management. <i>Annals of Medicine</i> , 2008, 40, 129-138.	3.8	84
297	Nitazoxanide for Severe Cryptosporidial Diarrhea in Human Immunodeficiency Virus Infected Children. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 1040-1041.	2.0	4
298	Human Immunodeficiency Virus-Infected Boy With Stevens-Johnson Syndrome Caused by Nevirapine. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 1041-1042.	2.0	3



#	ARTICLE	IF	CITATIONS
299	Toxic Epidermal Necrolysis Induced by Sulfonamide Eyedrops. <i>Cornea</i> , 2008, 27, 1068-1069.	1.7	17
300	Trimethoprim-Sulfamethoxazole for Osteoarthritis Caused by <i>Staphylococcus aureus</i> or <i>Kingella kingae</i> . <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 1042-1043.	2.0	6
301	Toxic Epidermal Necrolysis Clinical Guidelines. <i>Journal of Burn Care and Research</i> , 2008, 29, 706-712.	0.4	71
302	Nitazoxanide Treatment of <i>Cryptosporidium parvum</i> in Human Immunodeficiency Virus-Infected Children. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 1041.	2.0	4
303	Erupciones inflamatorias y purpúricas. , 2009, , 311-342.		0
304	Uso de inmunoglobulina humana endovenosa en pacientes con necrosis epidérmica tóxica y síndrome de sobreposición Stevens Johnson necrosis tóxica epidérmica. <i>Revista Medica De Chile</i> , 2009, 137, .	0.2	9
305	Fluconazole induced toxic epidermal necrolysis: a case report. <i>Cases Journal</i> , 2009, 2, 9071.	0.4	11
306	Acute Renal Failure and Its Risk Factors in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>American Journal of Nephrology</i> , 2009, 29, 633-638.	3.1	44
307	Defective Regulatory T Cells In Patients with Severe Drug Eruptions: Timing of the Dysfunction Is Associated with the Pathological Phenotype and Outcome. <i>Journal of Immunology</i> , 2009, 182, 8071-8079.	0.8	238
308	Neopterin and C-Reactive Protein in the Course of Stevens-Johnson Syndrome: Report of a Case. <i>Acta Dermato-Venereologica</i> , 2009, 89, 285-287.	1.3	1
309	Association of HLA-B*57:01 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2009, 75, 579.	0.6	272
310	Risk Factors for the Development of Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Archives of Dermatology</i> , 2009, 145, 157-62.	1.4	135
311	Fatal Toxic Epidermal Necrolysis Associated with Minoxidil. <i>Pharmacotherapy</i> , 2009, 29, 460-467.	2.6	14
312	Two cases of Stevens-Johnson syndrome following intake of klavox with review of literature. <i>European Archives of Oto-Rhino-Laryngology</i> , 2009, 266, 1327-1330.	1.6	7
314	Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. <i>International Journal of Dermatology</i> , 2009, 48, 1122-1128.	1.0	75
315	BSACI guidelines for the management of drug allergy. <i>Clinical and Experimental Allergy</i> , 2009, 39, 43-61.	2.9	205
316	Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2009, 7, 142-162.	0.8	66
317	The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. <i>Bipolar Disorders</i> , 2009, 11, 559-595.	1.9	159

#	ARTICLE	IF	CITATIONS
318	Clinical risk management of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. <i>Dermatologic Therapy</i> , 2009, 22, 441-451.	1.7	41
319	Medications as Risk Factors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children: A Pooled Analysis. <i>Pediatrics</i> , 2009, 123, e297-e304.	2.1	226
320	Diagnosis and Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis with Ocular Complications. <i>Ophthalmology</i> , 2009, 116, 685-690.	5.2	144
321	Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 589-594.	1.2	36
322	Successful Treatment of Stevens-Johnson Syndrome with Steroid Pulse Therapy at Disease Onset. <i>American Journal of Ophthalmology</i> , 2009, 147, 1004-1011.e1.	3.3	133
323	Acute Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis to Minimize Ocular Sequelae. <i>American Journal of Ophthalmology</i> , 2009, 147, 949-951.	3.3	16
324	Vision-Related Function After Scleral Lens Fitting in Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>American Journal of Ophthalmology</i> , 2009, 148, 852-859.e2.	3.3	79
326	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Overlap due to Oral Temozolomide and Cranial Radiotherapy. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 264-267.	6.7	25
327	An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. <i>Current Opinion in Pediatrics</i> , 2009, 21, 505-510.	2.0	61
330	High-Level Human Herpesvirus-6 Viremia Associated With Onset of Stevens-Johnson Syndrome: Report of Two Cases. <i>Journal of Burn Care and Research</i> , 2010, 31, 365-368.	0.4	20
331	Toxic Epidermal Necrolysis in Pregnancy: Case Report and Review of the Literature. <i>Journal of Burn Care and Research</i> , 2010, 31, 816-821.	0.4	23
332	Paraneoplastic Pemphigus in a Burn Intensive Care Unit: Case Report and Review of the Literature. <i>Journal of Burn Care and Research</i> , 2010, 31, 826-829.	0.4	11
333	Stevens-Johnson syndrome: a case report. <i>Journal of Oral Science</i> , 2010, 52, 343-346.	1.7	10
334	Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. <i>Intensive Care Medicine</i> , 2010, 36, 22-32.	8.2	51
335	Eritema multiforme. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2010, 17, 436-437.	0.0	0
336	<i>HLA-B*1511</i> is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. <i>Epilepsia</i> , 2010, 51, 2461-2465.	5.1	217
337	Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: Frozen-section diagnosis. <i>Journal of Dermatology</i> , 2010, 37, 407-412.	1.2	30
338	Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions. <i>Clinical and Experimental Dermatology</i> , 2010, 35, 863-868.	1.3	35

#	ARTICLE	IF	CITATIONS
339	ALDEN, an Algorithm for Assessment of Drug Causality in Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Caseâ€“Control Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 60-68.	4.7	529
340	Stevens Johnson syndrome after carbamazepine and SJS/TEN overlap syndrome after amoxicillin: s and a review. <i>Archives of Medical Science</i> , 2010, 1, 130-134.	0.9	4
341	Update on the Management of Antibiotic Allergy. <i>Allergy, Asthma and Immunology Research</i> , 2010, 2, 77.	2.9	46
342	The lichenoid reaction pattern (â€“interface dermatitisâ€“). , 2010, , 35-70.e41.		14
343	A Clinical Study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Efficacy of Treatment in Burn Intensive Care Unit. [Chapchi] <i>Journal Taehan Oekwa Hakhoe</i> , 2010, 78, 133.	1.1	4
344	Systemic inflammatory response syndrome in diseases of the skin. <i>Postgraduate Medical Journal</i> , 2010, 86, 83-88.	1.8	8
345	Caspofungin-Induced Severe Toxic Epidermal Necrolysis. <i>Annals of Pharmacotherapy</i> , 2010, 44, 1116-1118.	1.9	10
346	Beriplex â€“ the new generation haemorrhage stopper. <i>Journal of Obstetrics and Gynaecology</i> , 2010, 30, 872-873.	0.9	0
347	Severe Pneumonia Caused by Combined Infection with <i>Pneumocystis jiroveci</i> , Parainfluenza Virus Type 3, Cytomegalovirus, and <i>Aspergillus fumigatus</i> in a Patient with Stevens-Johnson Syndrome/toxic Epidermal Necrolysis. <i>Acta Dermato-Venereologica</i> , 2010, 90, 625-629.	1.3	10
348	Concurrence of Stevens-Johnson Syndrome and Bilateral Parotitis after Minocycline Therapy. <i>Case Reports in Dermatology</i> , 2010, 2, 88-94.	0.8	9
349	Functionally Active Macrophage-Derived Myeloperoxidase in the Skin of Drug-Induced Toxic Epidermal Necrolysis. <i>Dermatology</i> , 2010, 220, 201-207.	2.1	15
355	Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature. <i>American Journal of Health-System Pharmacy</i> , 2010, 67, 206-213.	1.0	67
356	CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 703-710.e8.	2.9	58
357	Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 1218-1225.e10.	2.9	59
358	Pharmacogenetics of toxic epidermal necrolysis. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2153-2162.	1.8	17
359	Toxic epidermal necrolysis and Stevens-Johnson syndrome. <i>Orphanet Journal of Rare Diseases</i> , 2010, 5, 39.	2.7	434
360	New Insights in Toxic Epidermal Necrolysis (Lyellâ€™s Syndrome). <i>Drug Safety</i> , 2010, 33, 189-212.	3.2	42
361	AquacelÂ® Ag with Vaseline gauze in the management of toxic epidermal necrolysis (TEN). <i>Burns</i> , 2010, 36, 121-126.	1.9	24

#	ARTICLE	IF	CITATIONS
362	Severe cutaneous adverse drug reactions: who should treat, where and how?: Facts and controversies. Clinics in Dermatology, 2010, 28, 344-348.	1.6	20
363	Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN. American Journal of Ophthalmology, 2010, 150, 505-510.e1.	3.3	74
364	Severe Cutaneous Adverse Reactions: Acute Generalized Exanthematous Pustulosis, Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome. Medical Clinics of North America, 2010, 94, 727-742.	2.5	40
365	Drug Allergy: An Updated Practice Parameter. Annals of Allergy, Asthma and Immunology, 2010, 105, 259-273.e78.	1.0	817
366	The Ophthalmologist's Role in the Management of Acute Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Ocular Surface, 2010, 8, 193-203.	4.4	24
367	Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert Opinion on Pharmacotherapy, 2010, 11, 423-439.	1.8	36
368	Early gynaecological assessment following Stevensâ€Johnson syndrome/toxic epidermal necrolysis. Journal of Obstetrics and Gynaecology, 2010, 30, 871-872.	0.9	3
369	A World Allergy Organization International Survey on Diagnostic Procedures and Therapies in Drug Allergy/Hypersensitivity. World Allergy Organization Journal, 2011, 4, 257-270.	3.5	46
372	Patient Experiences of Serious Adverse Drug Reactions and Their Attitudes to Medicines. Drug Safety, 2011, 34, 319-328.	3.2	52
374	The MASCC Textbook of Cancer Supportive Care and Survivorship. , 2011, , .		11
375	Shape and configuration of skin lesions: Targetoid lesions. Clinics in Dermatology, 2011, 29, 504-508.	1.6	16
376	Erythema marginatum hemorrhagicum: A unique cutaneous side effect of sorafenib. Journal of the American Academy of Dermatology, 2011, 64, 1194-1196.	1.2	7
377	Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole. Journal of the American Academy of Dermatology, 2011, 64, 1193-1194.	1.2	4
379	SEVERE, ACUTE ADVERSE CUTANEOUS DRUG REACTIONS I: STEVENSâ€JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS. , 0, , 154-161.		1
380	Severe Drug-Induced Skin Reactions: Clinical Pattern, Diagnostics and Therapy. , 2011, , .		10
381	Stevens-Johnson Syndrome Induced by Vandetanib. Annals of Dermatology, 2011, 23, S343.	0.9	22
382	Management of treatment-related dermatologic adverse effects. , 2011, , 115-120.		0
383	Toxic Epidermal Necrolysis Associated with Sorafenib and Tosufloxacin in a Patient with Hepatocellular Carcinoma. Annals of Dermatology, 2011, 23, S404.	0.9	8

#	ARTICLE	IF	CITATIONS
384	Evaluation of SCORTEN on a Cohort of Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Included in the RegiSCAR Study. <i>Journal of Burn Care and Research</i> , 2011, 32, 237-245.	0.4	65
385	In a Patient With Toxic Epidermal Necrolysis, Does Intravenous Immunoglobulin Improve Survival Compared With Supportive Care?. <i>Archives of Dermatology</i> , 2011, 147, 1437.	1.4	12
386	Severe Obliterative Bronchitis Associated with Stevens-Johnson Syndrome. <i>Internal Medicine</i> , 2011, 50, 2823-2827.	0.7	19
387	NKp46 <sup>+</sup> cells express granulysin in multiple cutaneous adverse drug reactions. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 1469-1476.	5.7	45
388	Hematological abnormalities and the use of granulocyte colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>International Journal of Dermatology</i> , 2011, 50, 1570-1578.	1.0	16
389	Evaluation of serum cytokine levels in toxic epidermal necrolysis and Stevens-Johnson syndrome compared with other delayed-type adverse drug reactions. <i>Journal of Dermatology</i> , 2011, 38, 1076-1079.	1.2	11
390	Pharmacogenetics of cutaneous adverse drug reactions. <i>Journal of Dermatology</i> , 2011, 38, 246-254.	1.2	91
392	Approach to the hospitalized patient with targetoid lesions. <i>Dermatologic Therapy</i> , 2011, 24, 196-206.	1.7	28
393	Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with paediatric patients in a University Hospital. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011, 25, 1153-1159.	2.4	51
394	Phenotype Standardization for Immune-Mediated Drug-Induced Skin Injury. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 896-901.	4.7	99
395	Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. <i>BMC Medical Genetics</i> , 2011, 12, 118.	2.1	170
396	EMPACT syndrome. <i>Cutaneous and Ocular Toxicology</i> , 2011, 30, 328-330.	1.3	7
397	Statistical Analysis of Stevens-Johnson Syndrome Caused by Mycoplasma pneumonia Infection in Japan. <i>Allergology International</i> , 2011, 60, 525-532.	3.3	53
399	Adverse Events After the Use of Benznidazole in Infants and Children With Chagas Disease. <i>Pediatrics</i> , 2011, 127, e212-e218.	2.1	137
400	Toxic Epidermal Necrolysis Associated with TS-1 in a Patient with Gastric Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 666-668.	1.3	10
401	Recurrence and Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children. <i>Pediatrics</i> , 2011, 128, 723-728.	2.1	139
402	Use of Intravenous Immunoglobulin in Toxic Epidermal Necrolysis. <i>Archives of Dermatology</i> , 2011, 147, 1440.	1.4	10
403	Severe cutaneous adverse reactions to antiepileptic drugs in Asians. <i>Neurology</i> , 2011, 77, 2025-2033.	1.1	97

#	ARTICLE	IF	CITATIONS
404	Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review*. Critical Care Medicine, 2011, 39, 1521-1532.	0.9	160
405	Investigation of Mannose-binding Lectin gene Polymorphism in Patients with Erythema Multiforme, Stevens Johnson Syndrome and Stevens Johnson Syndrome/Toxic Epidermal Necrolysis Overlap Syndrome. Balkan Medical Journal, 2012, 29, 310-3.	0.8	0
406	Herpes Zoster in Patients with Drug-induced Hypersensitivity Syndrome/DRESS. Acta Dermato-Venereologica, 2012, 92, 206-207.	1.3	13
407	Profile and Pattern of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a General Hospital in Singapore: Treatment Outcomes. Acta Dermato-Venereologica, 2012, 92, 62-66.	1.3	41
408	Can Vitamin B-Complex Aggravate the Carbamazepine Induced Toxic Epidermal Necrolysis?. Journal of Clinical and Diagnostic Research JCDR, 2012, 6, 1571-3.	0.8	2
409	How Epidemiology Has Contributed to a Better Understanding of Skin Disease. Journal of Investigative Dermatology, 2012, 132, 994-1002.	0.7	14
411	Genome-wide association study of serious blistering skin rash caused by drugs. Pharmacogenomics Journal, 2012, 12, 96-104.	2.0	31
412	<i>HLA-B*58:01</i> allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics, 2012, 13, 1193-1201.	1.3	92
413	Epidemiology of Cutaneous Adverse Drug Reactions. Chemical Immunology and Allergy, 2012, 97, 1-17.	1.7	71
414	Toxic epidermal necrolysis caused by fluconazole in a patient with human immunodeficiency virus infection. Journal of Pharmacology and Pharmacotherapeutics, 2012, 3, 276-278.	0.4	11
415	Toxic Epidermal Necrolysis. Journal of Burn Care and Research, 2012, 33, e295-e308.	0.4	52
416	The last word on the so-called "Rowell's syndrome". Lupus, 2012, 21, 577-585.	1.6	47
417	Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: a 3-year prospective study. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 839-846.	0.5	31
418	Proteomic Kinetic Analysis of Blister Fluid and Serum in a Patient with Drug-Induced Toxic Epidermal Necrolysis. A Comparison with Skin Immunohistochemistry. Current Drug Safety, 2012, 7, 339-351.	0.6	7
419	Toxic Epidermal Necrolysis in an Irradiated Patient Treated with a Nanocrystalline Silver Dressing. Case Reports in Dermatology, 2012, 4, 72-75.	0.8	3
420	Indications and Outcomes of Amniotic Membrane Transplantation in the Management of Acute Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Cornea, 2012, 31, 1394-1402.	1.7	79
421	Mycoplasma pneumoniae und Mukositis - Entität innerhalb des Spektrums des Stevens-Johnson-Syndroms. JDDG - Journal of the German Society of Dermatology, 2012, 10, 740-746.	0.8	6
422	The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. British Journal of Dermatology, 2012, 167, 555-562.	1.5	64

#	ARTICLE	IF	CITATIONS
423	Internet Accounts of Serious Adverse Drug Reactions. Drug Safety, 2012, 35, 1159-1170.	3.2	37
424	Incidence of Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome in an HIV Cohort. American Journal of Clinical Dermatology, 2012, 13, 49-54.	6.7	95
425	Acute skin failure. BMJ, The, 2012, 345, e5028-e5028.	6.0	1
426	Safety and Tolerability of Antiepileptic Drug Treatment in Children with Epilepsy. Drug Safety, 2012, 35, 519-533.	3.2	41
427	Toxic epidermal necrolysis in a 15-month-old girl successfully treated with amniotic membrane transplantation. Journal of AAPOS, 2012, 16, 478-480.	0.3	10
428	Skin Signs of Severe Systemic Medication Reactions. Current Problems in Pediatric and Adolescent Health Care, 2012, 42, 193-197.	1.7	0
429	S�ndrome de Stevens-Johnson. FMC Formacion Medica Continuada En Atencion Primaria, 2012, 19, 622-623.	0.0	0
430	Atlas of Dermatology in Internal Medicine. , 2012, , .		4
431	Acute compartment syndrome of the forearm as a rare complication of toxic epidermal necrolysis: a case report. Journal of Medical Case Reports, 2012, 6, 84.	0.8	3
432	A s�ndrome de Stevens-Johnson em pacientes neurocir�rgicos. Brazilian Neurosurgery, 2012, 31, 231-236.	0.1	0
433	Pharmacogenetics in psychiatry. , 0, , 53-68.		2
434	Causes and Treatment Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in 82 Adult Patients. Korean Journal of Internal Medicine, 2012, 27, 203.	1.7	50
435	Spontaneous adverse event reports of Stevens�Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications. Pharmacoepidemiology and Drug Safety, 2012, 21, 289-296.	1.9	29
436	Drug�induced Stevens�Johnson syndrome: case series from tertiary care centre in Gujarat. Pharmacoepidemiology and Drug Safety, 2012, 21, 384-395.	1.9	11
437	Validation of a claims�based diagnostic code for Stevens�Johnson syndrome in a commercially insured population. Pharmacoepidemiology and Drug Safety, 2012, 21, 760-764.	1.9	8
438	Lenalidomide cutaneous adverse event: a case of Stevens�Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone. Supportive Care in Cancer, 2012, 20, 1585-1587.	2.2	6
439	Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. British Journal of Dermatology, 2012, 166, 575-600.	1.5	69
440	A comprehensive 4-year survey of adverse drug reactions using a network-based hospital system. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 647-651.	1.5	16



#	ARTICLE	IF	CITATIONS
441	<i>Mycoplasma pneumoniae</i> and mucositis â€“ part of the Stevensâ€“Johnson syndrome spectrum. JDDG - Journal of the German Society of Dermatology, 2012, 10, 740-745.	0.8	39
442	Distinguishing between erythema multiforme major and Stevensâ€“Johnson syndrome/toxic epidermal necrolysis immunopathologically. Journal of Dermatology, 2012, 39, 781-786.	1.2	26
443	Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. British Journal of Dermatology, 2012, 167, 44-49.	1.5	84
444	Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. International Journal of Dermatology, 2012, 51, 889-902.	1.0	244
445	Stevensâ€“Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer. International Journal of Dermatology, 2012, 51, 864-867.	1.0	21
447	Toxic epidermal necrolysis. Journal of the American Academy of Dermatology, 2013, 69, 173.e1-173.e13.	1.2	396
448	Genetic association of IFN-Î³ +874T/A polymorphism in Mexican patients with drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Archives of Dermatological Research, 2013, 305, 353-357.	1.9	1
449	Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease. Rheumatology International, 2013, 33, 1351-1353.	3.0	17
450	Eritema multiforme fotodistribuido. Actas Dermo-sifiliogrÃ¡ficas, 2013, 104, 645-653.	0.4	14
452	A case of toxic epidermal necrolysis-like skin lesions with systemic lupus erythematosus and review of the literature. Lupus, 2013, 22, 839-846.	1.6	29
453	Characteristics of liver injury in drug-induced systemic hypersensitivity reactions. Journal of the American Academy of Dermatology, 2013, 69, 407-415.	1.2	68
454	Erythema multiforme major following treatment with infliximab. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 115, e36-e40.	0.4	21
456	Epidermal necrolysis (Stevensâ€“Johnson syndrome and toxic epidermal necrolysis): Historical considerations. Dermatologica Sinica, 2013, 31, 169-174.	0.5	10
457	Immunoglobulin injection for the treatment of multiple oral ulcers in Stevensâ€“Johnson syndrome. European Archives of Paediatric Dentistry: Official Journal of the European Academy of Paediatric Dentistry, 2013, 14, 355-358.	1.9	3
458	Bronchiolitis obliterans associated with Stevens-Johnson Syndrome: histopathological bronchial reconstruction of the whole lung and immunohistochemical study. Diagnostic Pathology, 2013, 8, 134.	2.0	23
459	The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. British Journal of Dermatology, 2013, 169, 1304-1309.	1.5	95
460	Prognostic value of histologic features of toxic epidermal necrolysis. Journal of the American Academy of Dermatology, 2013, 68, e29-e35.	1.2	34
461	Photodistributed Erythema Multiforme. Actas Dermo-sifiliogrÃ¡ficas, 2013, 104, 645-653.	0.4	5



#	ARTICLE	IF	CITATIONS
462	A Dire Reaction: Rash after Amiodarone Administration. American Journal of Medicine, 2013, 126, 301-303.	1.5	7
463	<scp>S</scp>tevensâ€“<scp>J</scp>ohnson syndrome and toxic epidermal necrolysis in subâ€“<scp>S</scp>aharan <scp>A</scp>frica: a multicentric study in four countries. International Journal of Dermatology, 2013, 52, 575-579.	1.0	38
464	A review of causes of Stevensâ€“Johnson syndrome and toxic epidermal necrolysis in children. Archives of Disease in Childhood, 2013, 98, 998-1003.	1.9	109
465	Question 2: Would systemic steroids be useful in the management of Stevens-Johnson syndrome?. Archives of Disease in Childhood, 2013, 98, 828-830.	1.9	10
466	<i>In vitro</i> drug causality assessment in Stevensâ€“Johnson syndrome â€“ alternatives for lymphocyte transformation test. Clinical and Experimental Allergy, 2013, 43, 1027-1037.	2.9	110
467	Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients. Journal of Allergy and Clinical Immunology, 2013, 131, 434-441.e9.	2.9	25
468	Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: Clinical evaluation and analysis of biomarkers. Journal of the American Academy of Dermatology, 2013, 69, 496-498.	1.2	55
469	Clinical Stevensâ€“Johnson syndrome and rufinamide: A clinical case. Allergologia Et Immunopathologia, 2013, 41, 68-69.	1.7	8
470	Urticaria Multiforme in an 18-Year-Old Girl. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 520-521.	3.8	4
471	Acute blistering diseases on the burn ward: Beyond Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis. Burns, 2013, 39, 1290-1296.	1.9	6
472	SCORTEN and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 628-633.	2.4	23
473	Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. British Journal of Dermatology, 2013, 168, 726-732.	1.5	100
474	Erythema Multiforme, Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis. , 2013, , 231-241.		1
475	Elevation of Conjunctival Epithelial CD45<sup>INT</sup>CD11b<sup>+</sup>CD16<sup>+</sup>CD14<sup>âˆ“</sup>Neutrophils in Ocular Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. , 2013, 54, 4578.		22
476	The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review. Therapeutic Advances in Drug Safety, 2013, 4, 246-253.	2.4	26
477	French referral center management of Stevensâ€“Johnson syndrome/toxic epidermal necrolysis. Dermatologica Sinica, 2013, 31, 191-195.	0.5	18
478	Specific HLA types are associated with antiepileptic drug-induced Stevensâ€“Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics, 2013, 14, 1821-1831.	1.3	60
479	<i>In vitro</i> diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. British Journal of Dermatology, 2013, 168, 539-549.	1.5	63

#	ARTICLE	IF	CITATIONS
480	Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. <i>British Journal of Dermatology</i> , 2013, 169, 1071-1080.	1.5	652
481	Lack of a Specific Humoral Autoreactivity in Sera from Patients with Early Erythema Exsudativum Multiforme Majus. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2799-2802.	0.7	3
482	A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. <i>Pharmacogenomics Journal</i> , 2013, 13, 60-69.	2.0	160
483	Comprehensive Survival Analysis of a Cohort of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1197-1204.	0.7	312
484	Toxic epidermal necrolysis. Report of two cases. Severe skin rash caused by common drugs. <i>Nasza Dermatologia Online</i> , 2013, 4, 517-521.	0.0	0
485	Retrospective analysis of Steven Johnson syndrome and toxic epidermal necrolysis over a period of 5 years from northern Karnataka, India. <i>Indian Journal of Pharmacology</i> , 2013, 45, 80.	0.7	17
486	Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: A prospective comparative open-labelled study of 36 cases. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2013, 79, 506.	0.6	42
487	Aceclofenac induced Stevens-Johnson/toxic epidermal necrolysis overlap syndrome. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2013, 4, 69.	0.4	5
488	A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2013, 79, 389.	0.6	87
489	A Case of Microstomia Subsequent to Toxic Epidermal Necrolysis Surgically Treated by Simple Technique. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2013, 1, e21.	0.6	2
490	Stevens-Johnson Syndrome and HIV in Children in Swaziland. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 1354-1358.	2.0	11
491	Serum antibody response to group II chaperonin from <i>Methanobrevibacter oralis</i> and human chaperonin CCT. <i>Pathogens and Disease</i> , 2013, 68, 12-19.	2.0	20
493	Pediatric Toxic Epidermal Necrolysis. <i>Journal of Burn Care and Research</i> , 2013, 34, e351-e358.	0.4	14
495	Toxic epidermal necrolysis induced by lansoprazole*. <i>Anais Brasileiros De Dermatologia</i> , 2013, 88, 117-120.	1.1	12
496	A 13-Year-Old Boy with Pharyngitis, Oral Ulcers, and Dehydration. <i>Pediatric Annals</i> , 2013, 42, 148-150.	0.8	7
497	Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective. <i>Asia Pacific Allergy</i> , 2013, 3, 215-223.	1.3	37
498	Effect of Age and Early Intervention with a Systemic Steroid, Intravenous Immunoglobulin or Amniotic Membrane Transplantation on the Ocular Outcomes of Patients with Stevens-Johnson Syndrome. <i>Korean Journal of Ophthalmology: KJO</i> , 2013, 27, 331.	1.1	38
499	Severe Cutaneous Adverse Reactions. , 0, , .		0

#	ARTICLE	IF	CITATIONS
500	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Medical and Societal Impact. Current Immunology Reviews, 2014, 10, 4-6.	1.2	1
501	Effector Cells and Downstream Mediators in Severe Cutaneous Adverse Reactions. Current Immunology Reviews, 2014, 10, 24-32.	1.2	2
502	Toxic epidermal necrolysis: a retrospective analysis of 17 cases from Central Tunisia. Pan African Medical Journal, 2014, 19, 269.	0.8	3
504	<i>Mycoplasma pneumoniae</i> Associated Mucocutaneous Disease in Children: Dilemmas in Classification. Pediatric Dermatology, 2014, 31, 670-675.	0.9	16
505	Retrospective Analysis of Corticosteroid Treatment in Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis over a Period of 10 Years in Vajira Hospital, Navamindradhiraj University, Bangkok. Dermatology Research and Practice, 2014, 2014, 1-5.	0.8	21
506	Cutaneous drug reactions in childhood. Journal of Clinical and Experimental Investigations, 2014, 5, .	0.3	0
507	The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 798-805.	5.7	88
509	Diclofenac-Serratiopeptidase Combination Induced Stevens Johnson Syndrome - A Rare Case Report with Review of Literature. Journal of Clinical and Diagnostic Research JCDR, 2014, 8, YD08-11.	0.8	2
510	Life-threatening dermatologic adverse events in oncology. Anti-Cancer Drugs, 2014, 25, 225-234.	1.4	61
511	Erythema Multiforme, Stevens Johnson Syndrome, and Toxic Epidermal Necrolysis Syndrome in Patients Undergoing Radiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 506-513.	1.3	27
512	Acute Respiratory Failure in Patients With Toxic Epidermal Necrolysis. Critical Care Medicine, 2014, 42, 118-128.	0.9	72
513	Stevens-John syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management. Seminars in Cutaneous Medicine and Surgery, 2014, 33, 10-16.	1.6	87
515	Stevens&ndash;Johnson Syndrome and toxic epidermalnecrolysis: a multi-aspect comparative 7-year study&nbsp;from the People&rsquo;s Republic of China. Drug Design, Development and Therapy, 2014, 8, 2539.	4.3	14
516	HLA Associations and Clinical Implications in T-Cell Mediated Drug Hypersensitivity Reactions: An Updated Review. Journal of Immunology Research, 2014, 2014, 1-8.	2.2	58
517	A successful pregnancy outcome after Stevens&quot;Johnson Syndrome. Journal of Obstetrics and Gynaecology, 2014, 34, 445-446.	0.9	8
518	Phenylbutazone-induced generalized bullous fixed drug eruption masquerading Stevens-Johnson syndrome/toxic epidermal necrolysis. International Journal of Nutrition, Pharmacology, Neurological Diseases, 2014, 4, 39.	0.5	0
520	HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4+ T cells. Journal of the American Academy of Dermatology, 2014, 70, 1096-1102.	1.2	39
521	Severe Cutaneous Adverse Reactions Related to Systemic Antibiotics. Clinical Infectious Diseases, 2014, 58, 1377-1385.	5.8	88

#	ARTICLE	IF	CITATIONS
522	Evidence of Neuropsychological Dysfunction in Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis: Case Report. <i>Clinical Neuropsychologist</i> , 2014, 28, 841-850.	2.3	1
523	Clinical Application of Pharmacogenomics: The Example of HLA-Based Drug-Induced Toxicity. <i>Public Health Genomics</i> , 2014, 17, 248-255.	1.0	18
524	Erythema multiforme, Stevensâ€“Johnson syndrome and toxic epidermal necrolysis: a comparative review. <i>Veterinary Dermatology</i> , 2014, 25, 406.	1.2	55
526	HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. <i>Pharmacogenomics Journal</i> , 2014, 14, 281-288.	2.0	199
527	Paracetamol induced Stevensâ€“Johnson syndrome â€“ toxic epidermal necrolysis overlap syndrome. <i>International Journal of Dermatology</i> , 2014, 53, 1042-1044.	1.0	22
528	Tear Exchangeable Limbal Rigid Contact Lens for Ocular Sequelae Resulting From Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis. <i>American Journal of Ophthalmology</i> , 2014, 158, 983-993.e1.	3.3	32
530	Management of Nonimmediate Hypersensitivity Reactions to Drugs. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 473-487.	1.9	20
531	Antiviral Drug Allergy. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 645-662.	1.9	10
532	Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 941-947.	1.2	144
533	A Topical Matter: Toxic Epidermal Necrolysis. <i>American Journal of Medicine</i> , 2014, 127, 931-932.	1.5	3
534	Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 442-445.	1.5	15
535	Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature. <i>British Journal of Dermatology</i> , 2014, 171, 1539-1545.	1.5	29
536	Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. <i>Burns</i> , 2014, 40, 1707-1712.	1.9	23
537	TNF-Î± as a useful predictor of human herpesvirus-6 reactivation and indicator of the disease process in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS). <i>Journal of Dermatological Science</i> , 2014, 74, 177-179.	1.9	14
538	An update on pediatric cutaneous drug eruptions. <i>Clinics in Dermatology</i> , 2014, 32, 516-523.	1.6	19
539	Toxic epidermal necrolysis (TEN): The Chelsea and Westminster Hospital wound management algorithm. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2014, 67, 1026-1032.	1.0	29
540	Hospital management and clinical factors associated with ophthalmic involvement in Toxic Epidermal Necrolysis. <i>Burns</i> , 2014, 40, 903-908.	1.9	3
541	Hypersensitivity to Antiepileptic Drugs. <i>Immunology and Allergy Clinics of North America</i> , 2014, 34, 633-643.	1.9	17

#	ARTICLE	IF	CITATIONS
542	Exudado uretral y afectación mucocutánea. Revista Clínica Española, 2014, 214, e91-e92.	0.6	2
543	Drug Induced Erythema Multiforme: Two Case Series with Review of Literature. Journal of Clinical and Diagnostic Research JCDR, 2014, 8, ZH01-4.	0.8	12
545	Drug-mediated rash: erythema multiforme versus Stevens-Johnson syndrome. BMJ Case Reports, 2014, 2014, bcr2014205543-bcr2014205543.	0.5	3
546	SJS/TEN Overlap Associated with Lomefloxacin: Case Report and Molecular Typing Studies. Dermatology, 2014, 229, 319-323.	2.1	3
547	Fatal case of cephalexin-induced toxic epidermal necrolysis. SAGE Open Medical Case Reports, 2014, 2, 2050313X1453225.	0.3	2
548	A Suspected Case of Efavirenz-Induced Stevens-Johnson Syndrome. Drug Safety - Case Reports, 2015, 2, 15.	0.9	6
549	Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. JDDG - Journal of the German Society of Dermatology, 2015, 13, 625-643.	0.8	62
550	Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Journal of Dermatology, 2015, 42, 768-777.	1.2	50
551	Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial. Trials, 2015, 16, 374.	1.6	4
552	Drugs causing severe ocular surface involvements in Japanese patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. Allergy International, 2015, 64, 379-381.	3.3	15
553	Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies. British Journal of Dermatology, 2015, 173, 1224-1231.	1.5	26
554	Occupational toxic epidermal necrolysis associated with dalbergia cochinchinensis: a retrospective comparative study of eight cases in China. International Journal of Dermatology, 2015, 54, 1435-1441.	1.0	7
555	Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions: a prospective comparative study. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 568-575.	5.7	49
556	Epidermal necrolysis: 60 years of errors and advances. British Journal of Dermatology, 2015, 173, 1250-1254.	1.5	53
557	A clinicotherapeutic analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORE of Toxic Epidermal Necrolysis. International Journal of Dermatology, 2015, 54, e18-26.	1.0	19
558	Ofloxacin Induced Cutaneous Reactions in Children. Journal of Clinical and Diagnostic Research JCDR, 2015, 9, FD01-2.	0.8	5
559	Predictive Factors Associated With Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. American Journal of Ophthalmology, 2015, 160, 228-237.e2.	3.3	104
560	Lamotrigine-induced severe cutaneous adverse reaction: Update data from 1999-2014. Journal of Clinical Neuroscience, 2015, 22, 1005-1011.	1.5	32

#	ARTICLE	IF	CITATIONS
561	Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms. <i>Asia Pacific Allergy</i> , 2015, 5, 59-67.	1.3	23
562	Schwere arzneimittelinduzierte Hautreaktionen: Klinik, Diagnostik, Ätiologie und Therapie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 625-645.	0.8	39
563	rs9263726 is a specific genetic marker for allopurinol-induced severe cutaneous adverse reactions in Chinese patients. <i>Personalized Medicine</i> , 2015, 12, 585-592.	1.5	6
564	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>JAMA Dermatology</i> , 2015, 151, 302.	4.1	31
565	The Role of Systemic Immunomodulatory Treatment and Prognostic Factors on Chronic Ocular Complications in Stevens-Johnson Syndrome. <i>Ophthalmology</i> , 2015, 122, 254-264.	5.2	48
566	IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1538-1545.e17.	2.9	55
567	Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience. <i>International Journal of Dermatology</i> , 2015, 54, 978-984.	1.0	30
568	<i>Mycoplasma pneumoniae</i> -induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 239-245.e4.	1.2	247
569	Mixed Signals: Toxic Epidermal Necrolysis. <i>American Journal of Medicine</i> , 2015, 128, 254-256.	1.5	2
570	Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2648-2651.	3.0	19
571	Toxic epidermal necrolysis secondary to <i>Mycoplasma pneumoniae</i> and herpes simplex virus infection. <i>Formosan Journal of Surgery</i> , 2015, 48, 37-43.	0.2	1
573	Clinical and Microscopic Characteristics of Canine Toxic Epidermal Necrolysis. <i>Veterinary Pathology</i> , 2015, 52, 321-330.	1.7	17
574	Risk of toxic epidermal necrolysis and Stevens-Johnson syndrome associated with benzodiazepines: a population-based cohort study. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 759-766.	1.9	15
575	A 15-Year Review of Pediatric Toxic Epidermal Necrolysis. <i>Journal of Burn Care and Research</i> , 2015, 36, 130-136.	0.4	41
576	Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. <i>Scientific Reports</i> , 2014, 4, 4862.	3.3	83
577	Development of a simple genotyping method for the HLA-A*31:01-tagging SNP in Japanese. <i>Pharmacogenomics</i> , 2015, 16, 1689-1699.	1.3	9
578	Nonbullous Erythema Multiforme in Hospitalized Children: A 10-Year Survey. <i>Pediatric Dermatology</i> , 2015, 32, 701-703.	0.9	8
579	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. <i>American Journal of Clinical Dermatology</i> , 2015, 16, 475-493.	6.7	151



#	ARTICLE	IF	CITATIONS
580	Outbreak of <i>Mycoplasma pneumoniae</i> Associated Stevens-Johnson Syndrome. <i>Pediatrics</i> , 2015, 136, e386-e394.	2.1	72
581	Stevens-Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission. <i>British Journal of Dermatology</i> , 2015, 172, 400-405.	1.5	26
582	Successful Treatment of Refractory Majocchi's Granuloma with Voriconazole and Review of Published Literature. <i>Mycopathologia</i> , 2015, 180, 237-243.	3.1	14
583	Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction. <i>Pharmacogenomics</i> , 2015, 16, 1989-2002.	1.3	10
584	Diclofenac sodium induced Stevens-Johnson syndrome in a hospitalized patient during treatment of splenic injury and mandibular fracture. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2015, 27, 29-32.	0.3	1
585	Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2157-2164.	0.9	160
586	Clinical features of and genetic predisposition to drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients investigating the relation between the HLA-B*4403 allele and lamotrigine. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 35-41.	1.9	25
587	Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Journal of Dermatology</i> , 2015, 42, 42-48.	1.2	35
588	Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. <i>International Journal of Dermatology</i> , 2015, 54, 108-115.	1.0	80
589	Ocular Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Hanyang Medical Reviews</i> , 2016, 36, 174.	0.4	6
590	Ibuprofen induced Stevens-Johnson syndrome - toxic epidermal necrolysis in Nepal. <i>Asia Pacific Allergy</i> , 2016, 6, 70-73.	1.3	25
591	Stunted root development: A rare dental complication of Stevens-Johnson syndrome. <i>Journal of Clinical and Experimental Dentistry</i> , 2016, 8, 0-0.	1.2	3
592	Incomum caso de eritema multiforme. <i>Revista Da Faculdade De Odontologia (Universidade De Passo)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 0,2	0,2	1
593	Toxic epidermal necrolysis and concurrent granulomatosis with polyangiitis (Wegener's) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 0,9 0	0,9	0
594	Long-term Sequelae of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. <i>Acta Dermato-Venereologica</i> , 2016, 96, 525-529.	1.3	81
596	HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs. <i>Yonsei Medical Journal</i> , 2016, 57, 118.	2.2	51
597	Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea. <i>PLoS ONE</i> , 2016, 11, e0165933.	2.5	89
598	Evaluation of the patients diagnosed with Stevens Johnson syndrome and toxic epidermal necrolysis: a single center experience. <i>Turk Pediatri Arsivi</i> , 2016, 51, 152-158.	0.9	6

#	ARTICLE	IF	CITATIONS
599	U.K. guidelines for the management of Stevensâ€Johnson syndrome/toxic epidermal necrolysis in adults 2016. British Journal of Dermatology, 2016, 174, 1194-1227.	1.5	199
600	Drugâ€induced liver injury associated with stevensâ€Johnson syndrome/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases. Hepatology, 2016, 63, 993-999.	7.3	55
601	Diagnostic patch testing following tuberculosisâ€associated cutaneous adverse drug reactions induces systemic reactions in <scp>HIV</scp> â€infected persons. British Journal of Dermatology, 2016, 175, 150-156.	1.5	43
602	Stevensâ€Johnson syndrome/toxic epidermal necrolysis caused by cefadroxil in a cat. Journal of Feline Medicine and Surgery Open Reports, 2016, 2, 205511691665361.	0.2	0
603	Ocular manifestations of Stevensâ€Johnson syndrome and their management. Current Opinion in Ophthalmology, 2016, 27, 522-529.	2.9	55
604	Administrative and Survey Data: Potential and Pitfalls. Journal of Investigative Dermatology, 2016, 136, 2122-2124.	0.7	7
605	Impact of the HLA-B58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions. Journal of Investigative Dermatology, 2016, 136, 1373-1381.	0.7	75
606	Ocular Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis inÃChildren. American Journal of Ophthalmology, 2016, 166, 68-75.	3.3	57
607	A case of Stevensâ€Johnson syndrome with gross hematuria. International Journal of Women's Dermatology, 2016, 2, 65-66.	2.0	1
608	In reply: Oral erythema multiforme: trends and clinical findings of a large retrospective: European case series. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 121, 681-682.	0.4	0
610	Burn Care for General Surgeons and General Practitioners. , 2016, , .		5
611	Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. Journal of Investigative Dermatology, 2016, 136, 1387-1397.	0.7	218
612	Exantema mucocutÃneo inducido por Mycoplasma pneumoniae: Ãun nuevo sÃndrome separado del eritema multiforme? Un nuevo caso y revisiÃ³n de la literatura. Actas Dermo-sifilogrÃficas, 2016, 107, e47-e51.	0.4	17
613	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention. American Journal of Medicine, 2016, 129, 1221-1225.	1.5	56
614	Increased risk of strontium ranelate-related SJS/TEN is associated with HLA. Osteoporosis International, 2016, 27, 2577-2583.	3.1	16
615	Presumed phenobarbital-induced Stevensâ€Johnson syndrome in a 4-year-old female Great Dane. Veterinary Quarterly, 2016, 36, 242-246.	6.7	2
616	Evaluation of Lymphocyte Transformation Test Results in Patients with Delayed Hypersensitivity Reactions following the Use of Anticonvulsant Drugs. International Archives of Allergy and Immunology, 2016, 170, 158-162.	2.1	29
617	A retrospective analysis of Stevensâ€Johnson syndrome/toxic epidermal necrolysis treated with corticosteroids. International Journal of Dermatology, 2016, 55, 1408-1413.	1.0	26



#	ARTICLE	IF	CITATIONS
619	Toxic epidermal necrolysis caused by acetaminophen featuring almost 100% skin detachment: Acetaminophen is associated with a risk of severe cutaneous adverse reactions. <i>Journal of Dermatology</i> , 2016, 43, 321-324.	1.2	11
620	Re-evaluation of "drug-induced" erythema multiforme in the medical literature. <i>British Journal of Dermatology</i> , 2016, 175, 650-651.	1.5	12
621	Drug induced exfoliative dermatitis: state of the art. <i>Clinical and Molecular Allergy</i> , 2016, 14, 9.	1.8	14
622	HLA and Delayed Drug-Induced Hypersensitivity. <i>International Archives of Allergy and Immunology</i> , 2016, 170, 163-179.	2.1	35
623	The use of porcine xenografts in patients with toxic epidermal necrolysis. <i>Burns</i> , 2016, 42, 1728-1733.	1.9	9
624	Das Dokumentationszentrum schwerer Hautreaktionen. , 2016, , 403-416.		1
625	<i>Mycoplasma pneumoniae</i> -Induced Mucocutaneous Rash: A New Syndrome Distinct from Erythema Multiforme? Report of a New Case and Review of the Literature. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2016, 107, e47-e51.	0.4	10
627	Deadly Dermatologic Diseases. , 2016, , .		2
628	Stevens Johnson syndrome/toxic epidermal necrolysis-overlap, induced by lacosamide. <i>European Journal of Dermatology</i> , 2016, 26, 185-186.	0.6	5
629	Successful Combination Therapy Including Plasma Exchange for Severe Toxic Epidermal Necrolysis. <i>Journal of General and Family Medicine</i> , 2016, 17, 232-237.	0.8	1
630	Two cases of overlap severe cutaneous adverse reactions to benznidazole treatment for asymptomatic Chagas disease in a nonendemic country. <i>British Journal of Dermatology</i> , 2016, 175, 604-607.	1.5	18
631	Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms. <i>British Journal of Dermatology</i> , 2016, 175, 944-952.	1.5	16
632	UK guidelines for the management of Stevensâ€™Johnson syndrome/toxic epidermal necrolysis in adults 2016. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2016, 69, e119-e153.	1.0	67
633	Predicting Mechanical Ventilation and Mortality. <i>Journal of Burn Care and Research</i> , 2016, 37, e47-e55.	0.4	7
634	Analysis of Ocular Manifestation and Genetic Association of Allopurinol-Induced Stevensâ€™Johnson Syndrome and Toxic Epidermal Necrolysis in South Korea. <i>Cornea</i> , 2016, 35, 199-204.	1.7	17
635	Severe cutaneous adverse drug reactions. <i>Journal of Dermatology</i> , 2016, 43, 758-766.	1.2	169
636	Burn unit care of Stevens Johnson syndrome/toxic epidermal necrolysis: A survey. <i>Burns</i> , 2016, 42, 830-835.	1.9	28
637	Toxicodermias graves: Â¿existen las formas combinadas?. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2016, 107, 23-33.	0.4	12

#	ARTICLE	IF	CITATIONS
638	Adverse cutaneous drug eruptions: current understanding. <i>Seminars in Immunopathology</i> , 2016, 38, 75-86.	6.1	112
639	Erythema Multiforme in Children and <i>Mycoplasma pneumoniae</i> Aetiology. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016, 20, 453-457.	1.2	24
640	Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for <i>Helicobacter pylori</i> . <i>Journal of Dermatology</i> , 2016, 43, 340-341.	1.2	11
641	Oral erythema multiforme: trends and clinical findings of a large retrospective: European case series. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 121, 681.	0.4	2
642	Indications for intubation and early tracheostomy in patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>American Journal of Surgery</i> , 2016, 211, 684-688.e1.	1.8	18
643	Severe adverse drug reactions. <i>Clinical Medicine</i> , 2016, 16, 79-83.	1.9	16
644	Severe Cutaneous Drug Reactions: Do Overlapping Forms Exist?. <i>Actas Dermo-sifiligráficas</i> , 2016, 107, 23-33.	0.4	2
645	A decade of burn unit experience with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Clinical pathological diagnosis and risk factor awareness. <i>Burns</i> , 2016, 42, 836-843.	1.9	30
646	Stevens-Johnson syndrome: The role of an ophthalmologist. <i>Survey of Ophthalmology</i> , 2016, 61, 369-399.	4.0	65
647	Oral ulcers and an unusual skin rash in a teenager. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2016, 29, 54-56.	0.3	1
648	Penicillins. , 2016, , 591-611.		1
649	Mucosal erosions as the presenting symptom in erythema multiforme: a case report. <i>British Journal of General Practice</i> , 2016, 66, e222-e224.	1.4	3
650	Rapid and reliable genotyping of <i>HLA-B*58:01</i> in four Chinese populations using a single-tube duplex real-time PCR assay. <i>Pharmacogenomics</i> , 2016, 17, 47-57.	1.3	7
651	Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients – Treatment and outcome. <i>Allergology International</i> , 2016, 65, 74-81.	3.3	81
652	Adverse drug reactions and organ damage: The skin. <i>European Journal of Internal Medicine</i> , 2016, 28, 17-24.	2.2	57
653	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Erythema Exsudativum Multiforme. , 2016, , 183-193.		1
654	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis – A Comprehensive Review and Guide to Therapy. I. Systemic Disease. <i>Ocular Surface</i> , 2016, 14, 2-19.	4.4	112
655	Stevens-Johnson syndrome after treatment with azithromycin: an uncommon culprit. <i>American Journal of Emergency Medicine</i> , 2016, 34, 676.e1-676.e3.	1.6	17

#	ARTICLE	IF	CITATIONS
656	Complications of Stevensâ€“Johnson syndrome beyond the eye and skin. Burns, 2016, 42, 20-27.	1.9	44
657	HLA-B*59:01: a marker for Stevensâ€“Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. Pharmacogenomics Journal, 2016, 16, 83-87.	2.0	50
658	HIV-Associated Toxic Epidermal Necrolysis at San Francisco General Hospital. Journal of the International Association of Providers of AIDS Care, 2017, 16, 37-41.	1.5	9
659	Pediatric Erythema Multiforme in the Emergency Department. Pediatric Emergency Care, 2017, 33, 320-324.	0.9	5
660	Toxic epidermal necrolysis: 13 years of experience in the management at a Department of Dermatology in China. Cutaneous and Ocular Toxicology, 2017, 36, 19-24.	1.3	10
661	Comparison of severe drug eruptions in Japan between 2005â€“2009 and 2010â€“2014 based on data from the relief system of the Pharmaceuticals and Medical Devices Agency. Journal of Dermatology, 2017, 44, e5-e6.	1.2	3
662	SÃndrome de Stevens-Johnson en la infancia. Archivos De La Sociedad Espanola De Oftalmologia, 2017, 92, 241-244.	0.2	2
663	Adverse drug reactions. Disease-a-Month, 2017, 63, 49-53.	1.1	2
664	Microbiological findings and antibacterial therapy in Stevensâ€“Johnson syndrome/toxic epidermal necrolysis patients from a Swedish Burn Center. Journal of Cutaneous Pathology, 2017, 44, 420-432.	1.3	13
665	Genetics and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. JAMA Ophthalmology, 2017, 135, 361.	2.5	1
666	Treatment of recurrent erythema multiforme with adalimumab as monotherapy. JAAD Case Reports, 2017, 3, 95-97.	0.8	12
667	Characterization of Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Admitted to Kenyatta National Hospital: A Retrospective Cross-Sectional Study. Drugs - Real World Outcomes, 2017, 4, 79-85.	1.6	15
668	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiologyâ€“Thirty Years of Progress but Still Much to Be Done. Journal of Investigative Dermatology, 2017, 137, 1004-1008.	0.7	66
669	Methotrexate-induced epidermal necrosis: A case series of 24 patients. Journal of the American Academy of Dermatology, 2017, 77, 247-255.e2.	1.2	35
670	Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 547-563.	3.8	106
671	Rash Decisions: An Approach to Dangerous Rashes Based on Morphology. Journal of Emergency Medicine, 2017, 52, 457-471.	0.7	9
672	Risk and association of <i>HLA</i> with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology, 2017, 88, 78-86.	1.1	117
673	The use of Biobrane Â® for wound coverage in Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis. Burns, 2017, 43, 1464-1472.	1.9	10

#	ARTICLE	IF	CITATIONS
674	Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2092-2100.	0.7	112
675	Gout: An old disease in new perspective – A review. <i>Journal of Advanced Research</i> , 2017, 8, 495-511.	9.5	329
676	Score of Toxic Epidermal Necrosis Predicts the Outcomes of Pediatric Epidermal Necrolysis. <i>Pediatric Dermatology</i> , 2017, 34, 433-437.	0.9	23
677	Pustular erythema multiforme major associated with atypical pneumonia. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e502-e503.	2.4	1
678	Mucositis Secondary to <i>Chlamydia pneumoniae</i> Infection: Expanding the <i>Mycoplasma pneumoniae</i> -Induced Rash and Mucositis Concept. <i>Pediatric Dermatology</i> , 2017, 34, 465-472.	0.9	31
679	Approach to Severe Cutaneous Adverse Drug Reactions. <i>Current Treatment Options in Allergy</i> , 2017, 4, 201-221.	2.2	2
680	Characterization of Children With Recurrent Episodes of Stevens Johnson Syndrome. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, e140-e143.	1.3	22
681	Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 757-763.	3.8	64
682	Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 811-817.e4.	1.2	83
683	Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Journal of Pediatric Urology</i> , 2017, 13, 490.e1-490.e7.	1.1	21
684	Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1065-1073.	0.7	109
685	Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 429-437.	1.5	87
686	Severe Delayed Drug Reactions. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 785-815.	1.9	27
687	Serum IL-17 in patients with erythema multiforme or Stevens-Johnson syndrome/toxic epidermal necrolysis drug reaction, and correlation with disease severity. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 868-873.	1.3	9
690	Oral health impacts of medications used to treat mental illness. <i>Journal of Affective Disorders</i> , 2017, 223, 184-193.	4.1	60
692	A clinicoetiological analysis of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis treated at Sohag University Hospital, Egypt. <i>Journal of the Egyptian Women's Dermatologic Society</i> , 2017, 14, 37-44.	0.1	3
693	Cutaneous adverse drug reactions: Kids are not just little people. <i>Clinics in Dermatology</i> , 2017, 35, 566-582.	1.6	11
694	Delayed-type hypersensitivity to oral and parenteral drugs. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1111-1132.	0.8	10

#	ARTICLE	IF	CITATIONS
695	Burn Center Care of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Clinics in Plastic Surgery</i> , 2017, 44, 583-595.	1.5	17
696	Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study. <i>BMC Ophthalmology</i> , 2017, 17, 65.	1.4	12
697	Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940-2015. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 14.	2.7	28
698	Patch testing - a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 280-287.	2.4	61
699	Apoptosis as a Mechanism for Keratinocyte Death in Canine Toxic Epidermal Necrolysis. <i>Veterinary Pathology</i> , 2017, 54, 249-253.	1.7	7
700	Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions. <i>Allergology International</i> , 2017, 66, 116-122.	3.3	27
701	Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 106-113.	1.2	64
702	A review of toxic epidermal necrolysis management in Japan. <i>Allergology International</i> , 2017, 66, 36-41.	3.3	32
703	Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. <i>Pharmacological Research</i> , 2017, 115, 168-178.	7.1	61
704	Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysis in adults. <i>International Journal of Dermatology</i> , 2017, 56, e78-e79.	1.0	1
705	Oxcarbazepine-induced Stevens-Johnson syndrome: a pediatric case report. <i>Oxford Medical Case Reports</i> , 2017, 2017, omx028.	0.4	4
706	Retrospective review of paediatric case reports of Stevens-Johnson syndrome and toxic epidermal necrolysis with lamotrigine from an international pharmacovigilance database. <i>BMJ Paediatrics Open</i> , 2017, 1, e000039.	1.4	13
707	Spättypreaktionen auf oral und parenteral verabreichte Arzneimittel. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1111-1134.	0.8	4
708	TOXIC EPIDERMAL NECROLYSIS INDUCED BY CARBAMAZEPINE: A CASE STUDY. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2017, 10, 78.	0.3	3
709	Incidence, causative drugs, and economic consequences of drug-induced SJS, TEN, and SJS&ndash;TEN overlap and potential drug&ndash;drug interactions during treatment: a retrospective analysis at an Indonesian referral hospital. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 919-925.	2.0	12
710	Paediatric Erythema Multiforme: Epidemiological, Clinical and Laboratory Characteristics. <i>Acta Dermato-Venereologica</i> , 2017, 97, 489-492.	1.3	38
711	Factors Contributing to Long-Term Severe Visual Impairment in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Journal of Ophthalmology</i> , 2017, 2017, 1-7.	1.3	15
712	Treatments for Severe Cutaneous Adverse Reactions. <i>Journal of Immunology Research</i> , 2017, 2017, 1-9.	2.2	40

#	ARTICLE	IF	CITATIONS
714	A Comparative Insight into the Incidence of Steven Johnson Syndrome/ Toxic Epidermal Necrolysis among the Immunocompromized Patient Populace of Eastern India with a Distinctive Emphasis on the Possible Association of Human Cytomegalovirus. Journal of AIDS & Clinical Research, 2017, 08, .	0.5	1
715	Phenytoin-induced Stevens-Johnson syndrome with myocarditis: a rare case report. International Medical Case Reports Journal, 2017, Volume 10, 229-231.	0.8	5
716	Retrospective Analysis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in 88 Chinese Patients. Chinese Medical Journal, 2017, 130, 1062-1068.	2.3	22
717	Stevens-Johnson syndrome and abuse of anabolic steroids. Journal of the Korean Association of Oral and Maxillofacial Surgeons, 2017, 43, 57.	0.8	5
718	Farmacogenética de reacciones adversas a fármacos antiepilépticos. Neurología, 2018, 33, 165-176.	0.7	27
719	Risks associated with lamotrigine prescription: a review and personal observations. Australasian Psychiatry, 2018, 26, 640-642.	0.7	11
720	Pediatric Lip Adhesion Following Bullous Erythema Multiforme and Review of Similar Oral Complications. Journal of Cutaneous Medicine and Surgery, 2018, 22, 427-430.	1.2	3
721	The measurement of drug-induced interferon $\gamma$ -releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 992-998.	2.4	30
722	Nursing care of a boy seriously infected with Steven's-Johnson syndrome after treatment with azithromycin. Medicine (United States), 2018, 97, e9112.	1.0	14
723	How Does SCORTEN Score?. Journal of Burn Care and Research, 2018, 39, 555-561.	0.4	17
724	Histopathology of Cutaneous Inflammatory Disorders in Children. Pediatric and Developmental Pathology, 2018, 21, 115-149.	1.0	2
725	From HSV infection to erythema multiforme through autoimmune crossreactivity. Autoimmunity Reviews, 2018, 17, 576-581.	5.8	18
726	Ethosuximide-induced Stevens-Johnson syndrome: Beneficial effect of early intervention with high-dose corticosteroid therapy. Journal of Dermatology, 2018, 45, 592-595.	1.2	7
728	Current Perspectives on Erythema Multiforme. Clinical Reviews in Allergy and Immunology, 2018, 54, 177-184.	6.5	85
729	Management of severe drug reactions: a retrospective monocentric analysis. Allergo Journal International, 2018, 27, 49-55.	2.0	0
730	Pharmacogenetics of adverse reactions to antiepileptic drugs. Neurología (English Edition), 2018, 33, 165-176.	0.4	5
731	Specific association of the rs6500265 and rs9933632 single-nucleotide polymorphisms in Japanese patients with antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements. Pharmacogenetics and Genomics, 2018, 28, 95-98.	1.5	1
734	The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions. Journal of Investigative Dermatology, 2018, 138, 1546-1554.	0.7	54

#	ARTICLE	IF	CITATIONS
735	The Frequency and Clinical Features of Hypersensitivity Reactions to Antiepileptic Drugs in Children: A Prospective Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 2043-2050.	3.8	18
737	Delayedâ€type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro Tâ€cell reactivity study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 221-229.	5.7	41
738	Severe sequelae of erythema multiforme: three cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e34-e36.	2.4	9
739	Chronic ocular complications of Stevens-Johnson syndrome associated with causative medications in Korea. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 700-702.e2.	3.8	10
740	Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience. <i>Burns</i> , 2018, 44, 603-611.	1.9	30
741	Drug Allergy. , 2018, , 19-26.		6
742	Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 147-176.	6.5	218
744	Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2018, 6, 730-738.	0.2	29
745	Drug Allergy and Adverse Drug Reactions. , 2018, , 1-14.		0
747	ACECLOFENAC-INDUCED STEVENS-JOHNSON SYNDROME AFTER ONE SINGLE DOSE: A MAIDEN CASE REPORT. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2018, 11, 1.	0.3	5
749	An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. <i>Journal of Immunology Research</i> , 2018, 2018, 1-22.	2.2	111
750	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the Unitedâ€States. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2315-2321.	0.7	94
751	Care in patients with epidermal necrolysis in burn units. A nursing perspective. <i>Burns</i> , 2018, 44, 1962-1972.	1.9	10
752	Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. <i>Cancer Management and Research</i> , 2018, Volume 10, 1259-1273.	1.9	109
753	Active surveillance of severe cutaneous adverse reactions: A caseâ€population approach using a registry and a health care database. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 1042-1050.	1.9	12
754	Management and outcome of Stevensâ€Johnson syndrome and toxic epidermal necrolysis in patients admitted to Kenyatta National Hospital. <i>Drugs and Therapy Perspectives</i> , 2018, 34, 444-450.	0.6	0
756	A meta-analysis of cyclosporine treatment for Stevens&ndash;Johnson syndrome/toxic epidermal necrolysis. <i>Journal of Inflammation Research</i> , 2018, Volume 11, 135-142.	3.5	58
757	Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1453-1463.	2.9	30



#	ARTICLE	IF	CITATIONS
758	Chronic pulmonary complications associated with toxic epidermal necrolysis: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 2027-2031.	1.8	6
759	Procalcitonin as a diagnostic indicator for systemic bacterial infections in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Journal of Dermatology</i> , 2018, 45, 989-993.	1.2	10
760	Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>Pediatrics International</i> , 2018, 60, 697-702.	0.5	25
761	Analysis of HLA-B Allelic Variation and IFN- $\gamma$ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 219-227.e4.	3.8	36
762	Rashes and other hypersensitivity reactions associated with antiepileptic drugs: A review of current literature. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2019, 71, 270-278.	2.0	24
763	Drug-induced severe cutaneous adverse reactions. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 483-487.	1.0	30
764	Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation—A retrospective chart review. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 749-757.	1.2	24
765	Galectin-7 as a potential biomarker of Stevens-Johnson syndrome/toxic epidermal necrolysis: identification by targeted proteomics using causative drug-exposed peripheral blood cells. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2894-2897.e7.	3.8	13
766	Carbonic anhydrase inhibitor—induced Stevens-Johnson syndrome/toxic epidermal necrolysis leads to extensive cutaneous involvement. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2851-2853.e2.	3.8	6
767	Outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in HIV-infected patients when using systemic steroids and/or intravenous immunoglobulins in Pietermaritzburg, South Africa. <i>Southern African Journal of HIV Medicine</i> , 2019, 20, 944.	0.9	8
768	Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 686-693.	1.2	24
769	Long-Term Effect of a Treatment Protocol for Acute Ocular Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. <i>American Journal of Ophthalmology</i> , 2019, 208, 331-341.	3.3	38
770	Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with immune checkpoint inhibitor. <i>Journal of Dermatology</i> , 2019, 46, e434-e436.	1.2	8
771	Ocular manifestations in patients with Stevens-Johnson syndrome in Malawi—review of the literature illustrated by clinical cases. <i>Graefes' Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 2343-2348.	1.9	6
772	Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2739-2749.e3.	3.8	17
773	Unusual oral findings of the toxic epidermal necrolysis in an HIV-infected patient: a case report. <i>Brazilian Journal of Infectious Diseases</i> , 2019, 23, 363-367.	0.6	3
774	Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment. <i>Allergo Journal International</i> , 2019, 28, 311-326.	2.0	15
775	Life-Threatening Extrarenal Manifestations in an Infant with Atypical Hemolytic Uremic Syndrome Caused by a Complement 3-Gene Mutation. <i>Kidney and Blood Pressure Research</i> , 2019, 44, 1300-1305.	2.0	1



#	ARTICLE	IF	CITATIONS
776	Allopurinol-Induced Toxic Epidermal Necrolysis. Drug Safety - Case Reports, 2019, 6, 8.	0.9	3
777	Interventions for erythema multiforme: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 842-849.	2.4	20
778	Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population-Based Cohort Study and Meta-Analysis. Clinical Pharmacology and Therapeutics, 2019, 106, 391-401.	4.7	34
779	Drug Allergy and Adverse Drug Reactions. , 2019, , 491-504.		0
780	Association of Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs in pediatric patients: Subgroup analysis based on a Japanese spontaneous database. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 775-779.	1.5	16
781	Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study. International Journal of Dermatology, 2019, 58, 1293-1299.	1.0	16
782	Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. Drug Safety, 2019, 42, 973-992.	3.2	66
783	Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database. American Journal of Clinical Dermatology, 2019, 20, 579-592.	6.7	19
784	Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10. JAMA Dermatology, 2019, 155, 448.	4.1	69
786	Oral Signs of Vesiculobullous and Autoimmune Disease. , 2019, , 113-144.		0
787	A 10-year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens-Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016. International Journal of Dermatology, 2019, 58, 1141-1147.	1.0	12
788	Ocular and Mucocutaneous Sequelae among Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Togo. Dermatology Research and Practice, 2019, 2019, 1-6.	0.8	6
789	White and Red Lesions of the Oral Mucosa. , 2019, , 1207-1248.		5
790	Pediatric Oral Medicine. , 2019, , 1641-1718.		2
791	Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients. Anais Brasileiros De Dermatologia, 2019, 94, 17-23.	1.1	8
792	Phenotypes and Natural Evolution of Drug Hypersensitivity. Current Treatment Options in Allergy, 2019, 6, 27-41.	2.2	2
793	Multistep Grading System for Evaluation of Chronic Ocular Sequelae in Patients With Stevens-Johnson Syndrome. American Journal of Ophthalmology, 2019, 203, 69-77.	3.3	12
794	Un lupus érythémateux systémique se présentant sous la forme d'un syndrome de Stevens-Johnson. Revue Française D'allergologie, 2019, 59, 418-420.	0.2	0

#	ARTICLE	IF	CITATIONS
795	A Review of the Management of Stevensâ€“Johnson Syndrome and Toxic Epidermal Necrolysis. Advanced Emergency Nursing Journal, 2019, 41, 56-64.	0.5	21
796	Toxic Epidermal Necrolysis Induced by Leflunomide in a Patient With Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2019, Publish Ahead of Print, .	0.9	3
798	An atypical presentation of toxic epidermal necrolysis without mucosal involvement. Medical Journal Armed Forces India, 2019, 78, 106-108.	0.8	2
799	Characteristics of meibomian gland dysfunction in patients with Stevensâ€“Johnson syndrome. Medicine (United States), 2019, 98, e16155.	1.0	12
800	Making a diagnosis in severe cutaneous drug hypersensitivity reactions. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 283-293.	2.3	38
801	Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: a Review and Update. Current Dermatology Reports, 2019, 8, 219-233.	2.1	7
803	Deep Inferior Epigastric Artery Perforator Flap Breast Reconstruction in a Patient with a History of Toxic Epidermal Necrosis. Plastic and Reconstructive Surgery - Global Open, 2019, 7, e2190.	0.6	0
804	A Case Study of Toxic Epidermal Necrolysis. Journal of Pediatric Surgical Nursing, 2019, 8, 74-78.	0.1	0
805	Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity. BMJ Case Reports, 2019, 12, e230144.	0.5	6
806	Ocular, Aural, and Oral Manifestations of Lupus. , 2019, , 556-565.		3
807	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). , 2019, , 87-104.		1
808	Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions. , 2019, , .		6
809	Serum and blisterâ€“fluid elevation and decreased epidermal content of highâ€“mobility group box 1 protein in drugâ€“induced Stevensâ€“Johnson syndrome/toxic epidermal necrolysis. British Journal of Dermatology, 2019, 181, 166-174.	1.5	15
811	Dermatologic Conditions of the Early Post-Transplant Period in Hematopoietic Stem Cell Transplant Recipients. American Journal of Clinical Dermatology, 2019, 20, 55-73.	6.7	5
812	The rash that presents as target lesions. Clinics in Dermatology, 2019, 37, 148-158.	1.6	4
813	Drugâ€“induced liver injury with skin reactions: Drugs and host risk factors, clinical phenotypes and prognosis. Liver International, 2019, 39, 802-811.	3.9	23
814	Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. European Journal of Clinical Pharmacology, 2019, 75, 237-246.	1.9	16
815	<sc>HLA</sc> Alleles and <i><sc>CYP</sc>2C9*3</i> as Predictors of Phenytoin Hypersensitivity in East Asians. Clinical Pharmacology and Therapeutics, 2019, 105, 476-485.	4.7	53

#	ARTICLE	IF	CITATIONS
816	The Medication Risk of Stevensâ€Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 112-120.	4.7	54
817	Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. <i>Journal of Dermatological Treatment</i> , 2020, 31, 66-73.	2.2	38
818	Treatment for oral lesions in pediatric patients with Stevensâ€Johnson's syndrome: A case report and literature review. <i>International Journal of Paediatric Dentistry</i> , 2020, 30, 489-496.	1.8	6
819	Characteristics of cutaneous adverse drug reactions caused by tripleâ€combination drug therapy used for <i>Helicobacter pylori</i> eradication. <i>Journal of Dermatology</i> , 2020, 47, 277-282.	1.2	4
820	Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999â€2017. <i>Vaccine</i> , 2020, 38, 1746-1752.	3.8	29
821	Adverse Reactions Associated with Penicillins, Carbapenems, Monobactams, and Clindamycin: A Retrospective Population-based Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1302-1313.e2.	3.8	31
822	Quick Guide to Anaphylaxis. , 2020, , .		0
823	Accuracy of SCORTEN to predict the prognosis of Stevensâ€Johnson syndrome/toxic epidermal necrolysis: a systematic review and metaâ€analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2066-2077.	2.4	26
824	Confusion in determination of two types of cutaneous adverse reactions to drugs, maculopapular eruption and erythema multiforme, among the experts: A proposal of standardized terminology. <i>Journal of Dermatology</i> , 2020, 47, 169-173.	1.2	3
825	Pembrolizumab-Induced Stevensâ€Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report. <i>American Journal of Dermatopathology</i> , 2020, 42, 292-296.	0.6	21
826	Mycoplasma pneumoniae-Induced Rash and Mucositis in a Previously Healthy Man: A Case Report and Brief Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa437.	0.9	3
827	Assessment and Comparison of Performance of ABCD-10 and SCORTEN in Prognostication of Epidermal Necrolysis. <i>JAMA Dermatology</i> , 2020, 156, 1294.	4.1	25
828	Recurrent Stevensâ€Johnson syndrome in a patient with systemic lupus erythematosus: a case report. <i>Journal of International Medical Research</i> , 2020, 48, 030006052096434.	1.0	0
829	Ocular manifestations of mycoplasma-induced rash and mucositis. <i>Journal of AAPOS</i> , 2020, 24, 249-251.	0.3	6
830	HLA genotypes and cold medicine-induced Stevensâ€Johnson syndrome/toxic epidermal necrolysis with severe ocular complications: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 10589.	3.3	12
831	The use of biostatic human amnion and plateletâ€rich plasma in topical treatment of toxic epidermal necrolysisâ€A case report. <i>Journal of Cosmetic Dermatology</i> , 2020, 20, 2887-2893.	1.6	2
832	Antiepileptic combination therapy with Stevensâ€Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database. <i>Epilepsia</i> , 2020, 61, 1979-1989.	5.1	18
833	Analysis of severity and preventability in patients ofâ€Toxic epidermal necrolysisâ€A case series. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2452-2456.	0.5	1

#	ARTICLE	IF	CITATIONS
834	HLA-B*58:01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 153-160.	1.5	8
835	Accuracy of SCORTEN and ABCD <sup>2</sup> to predict mortality and the influence of renal function in Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Journal of Dermatology</i> , 2020, 47, 1182-1186.	1.2	16
836	Drug induced liver injury: an update. <i>Archives of Toxicology</i> , 2020, 94, 3381-3407.	4.2	125
837	Approaching Target and Targetoid Eruptions in Inpatient Dermatology. <i>Current Dermatology Reports</i> , 2020, 9, 210-219.	2.1	0
838	Toxic epidermal necrolysis syndrome induced by tigecycline: a case report. <i>Journal of International Medical Research</i> , 2020, 48, 030006052092241.	1.0	2
839	Cancer immunotherapy and toxic epidermal necrolysis. <i>BMJ Supportive and Palliative Care</i> , 2020, 10, 314-315.	1.6	2
840	Ventilatory support in Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. <i>Journal of Dermatological Treatment</i> , 2020, , 1-6.	2.2	1
841	Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis "diagnosis and treatment. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 547-553.	0.8	23
842	A CASE REPORT ON LAMOTRIGINE AND SODIUM VALPROATE INDUCED STEVENS-JOHNSON SYNDROME. <i>International Research Journal of Pharmacy</i> , 2020, 11, 1-4.	0.2	1
843	Clinical trial to evaluate the therapeutic benefits of limbal-supported contact lens wear for ocular sequelae due to Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Contact Lens and Anterior Eye</i> , 2020, 43, 535-542.	1.7	9
845	Multidisciplinary care in Stevens-Johnson syndrome. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062231989446.	2.5	34
846	General characteristics, economic burden, causative drugs and medical errors associated with medical damage litigation involving severe cutaneous adverse drug reactions in China. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1087-1097.	1.5	3
847	Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 373-387.	3.0	20
848	Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1957-1971.	2.4	25
849	Stevens-Johnson Syndrome-Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2020, 8, 232470962091479.	0.6	13
850	Severe cutaneous adverse drug reactions manifesting as Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the national pharmacovigilance center in Nigeria: a database review from 2004 to 2017. <i>Therapeutic Advances in Drug Safety</i> , 2020, 11, 204209862090599.	2.4	13
851	Severe Cutaneous Adverse Reactions to Drugs in Latin America: The RACGRAD Study. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2021, 31, 322-331.	1.3	6
852	Erythema Multiforme Major in a Dog Treated with Intravenous Human Immunoglobulin and Immunosuppressive Therapy. <i>Journal of the American Animal Hospital Association</i> , 2020, 56, 133-138.	1.1	5

#	ARTICLE	IF	CITATIONS
853	Adverse cutaneous reactions to chemotherapeutic drugs. <i>Clinics in Dermatology</i> , 2020, 38, 712-728.	1.6	14
854	Clinical Utility of <i>HLA-B*58:01</i> Genotyping to Prevent Allopurinol-Induced SJS/TEN. <i>Hospital Pharmacy</i> , 2021, 56, 660-663.	1.0	4
855	Association of HLA-A*11:01 with Sulfonamide-Related Severe Cutaneous Adverse Reactions in Japanese Patients. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1659-1662.e6.	0.7	18
856	DRESS syndrome after lamotrigine and valproic acid use in a bipolar patient: a case report. <i>European Journal of Psychiatry</i> , 2020, 34, 160-163.	1.3	1
857	Long-term outcomes of amniotic membrane treatment in acute Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Ocular Surface</i> , 2020, 18, 517-522.	4.4	42
858	Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 644-653.	1.2	5
859	Management of oral medicine emergencies during COVID-19: A study to develop practise guidelines. <i>Journal of Dental Sciences</i> , 2021, 16, 493-500.	2.5	16
860	Intensive care needs and long-term outcome of pediatric toxic epidermal necrolysis – A 10-year experience. <i>International Journal of Dermatology</i> , 2021, 60, 44-52.	1.0	4
861	Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1402-1412.	2.9	46
862	A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 929-936.e7.	3.8	18
863	The risk of anti-osteoporotic agent-induced severe cutaneous adverse drug reactions and their association with HLA. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 712-720.	2.4	8
864	Differences between Stevens-Johnson syndrome versus toxic epidermal necrolysis. <i>International Journal of Dermatology</i> , 2021, 60, 53-59.	1.0	6
865	Investigating the association of Lamotrigine and Phenytoin-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis with HLA-B*1502 in Iranian population. <i>Experimental Dermatology</i> , 2021, 30, 284-287.	2.9	10
866	Mortality and risk factors on admission in toxic epidermal necrolysis: A cohort study of 59 patients. <i>Allergology International</i> , 2021, 70, 229-234.	3.3	16
867	Sifting through the history of the nosology of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis and its clinicopathological relevance. <i>International Journal of Dermatology</i> , 2021, 60, 110-112.	1.0	1
868	When is a rash not “just” a rash? A guide to recognition and treatment of paediatric dermatological emergencies. <i>Paediatrics and Child Health (United Kingdom)</i> , 2021, 31, 46-54.	0.4	1
869	Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 390-397.	1.2	56
870	Levamisole induced toxic epidermal necrolysis: A case report. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1574-1577.	2.4	3

#	ARTICLE	IF	CITATIONS
871	Macules or papules? No small matter!. International Journal of Dermatology, 2021, 60, .	1.0	0
872	The Roles of Immunoregulatory Networks in Severe Drug Hypersensitivity. Frontiers in Immunology, 2021, 12, 597761.	4.8	15
873	Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. Frontiers in Oncology, 2021, 11, 621591.	2.8	29
874	HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients. Frontiers in Immunology, 2021, 12, 661135.	4.8	29
875	Erythema Multiforme Major Associated With Community-Acquired Pneumonia: Lessons From a Case Report. Frontiers in Pediatrics, 2021, 9, 698261.	1.9	6
876	Recent Dermatological Treatments for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Japan. Frontiers in Medicine, 2021, 8, 636924.	2.6	9
877	TRIMETHOPRIM-SULFAMETHOXAZOLE AND SODIUM VALPROATE-INDUCED TOXIC EPIDERMAL NECROLYSIS: A CASE SERIES. Asian Journal of Pharmaceutical and Clinical Research, 0, , 3-5.	0.3	1
878	Case Report: Positive Outcome of a Suspected Drug-Associated (Immune Mediated) Reaction in a 4-Year-Old Male French Bulldog. Frontiers in Veterinary Science, 2021, 8, 728901.	2.2	1
879	Sequential Blood Purification for Pediatric Fatal Toxic Epidermal Necrolysis: A Case Series. Blood Purification, 2021, , 1-8.	1.8	2
880	Drug-related Stevensâ€”Johnson Syndrome and Toxic Epidermal Necrolysis: A Review. Indian Journal of Critical Care Medicine, 2021, 25, 575-579.	0.9	8
882	Schwere Arzneimittel-induzierte Hautreaktionen. , 2005, , 447-454.		1
883	Severe Cutaneous Adverse Reactions. , 2009, , 473-484.		23
884	The management of adverse drug reactions. Clinical Reviews in Allergy and Immunology, 1995, 13, 281-290.	6.5	1
885	Erythema Multiforme and Toxic Epidermal Necrolysis: A Comparative Study. American Journal of Dermatopathology, 1997, 19, 127-132.	0.6	94
886	The Spectrum of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Clinical Classification.. Journal of Investigative Dermatology, 1994, 102, 28S-30S.	0.7	301
887	Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevensâ€”Johnson syndrome and toxic epidermal necrolysis. British Journal of Dermatology, 1996, 135, 6-11.	1.5	128
888	Use of Intravenous Immunoglobulin in Children With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Seven Cases and Review of the Literature. Pediatrics, 2003, 112, 1430-1436.	2.1	122
889	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Pediatric Annals, 2010, 39, 667-674.	0.8	4

#	ARTICLE	IF	CITATIONS
890	Drug Allergy in Pediatric Patients. <i>Pediatric Annals</i> , 2011, 40, 200-204.	0.8	4
891	Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis over a period of 10 years. <i>Indian Journal of Dermatology</i> , 2011, 56, 25.	0.3	33
892	Herpes Simplex Associated Erythema Multiforme: A Case Report and Review of the Literature. <i>Acta Medica Bulgarica</i> , 2021, 48, 46-48.	0.1	0
893	A Child Case of Severe Drug Eruption-It is Difficult to Judge the Causative Drug.. <i>Nishinihon Journal of Dermatology</i> , 2000, 62, 636-638.	0.0	0
894	Vesiculo-bulleuze dermatosen. , 2004, , 138-144.		0
895	Diagnosis and Treatment of Drug Eruption-Symptoms and Causative Agents of Severe Cutaneous Adverse Reaction-. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2006, 2, 103-107.	0.0	0
896	A Case of Toxic Epidermal Necrolysis Initially Affecting the Skin Site of Radiation Therapy for an Intra-cranial Post-transplantation Lymphoma. <i>Nishinihon Journal of Dermatology</i> , 2006, 68, 46-50.	0.0	0
897	Kutane Arzneimittelreaktionen: Spektrum und Diagnostik. <i>Fortschritte Der Praktischen Dermatologie Und Venerologie</i> , 2009, , 160-162.	0.0	0
898	Stevensâ€”Johnson Syndrome and Toxic Epidermal Necrolysis. , 2009, , 87-95.		0
899	Fever and Rash in Critical Care. <i>Infectious Disease and Therapy</i> , 2009, , 19-48.	0.0	0
900	Fever and Rash in Critical Care. <i>Infectious Disease and Therapy</i> , 2009, , 19-48.	0.0	0
902	Alan Lyell et le syndrome de Lyell. , 2011, , 123-129.		0
903	Allergic, Toxic, and Drug-Induced Eruptions of the Oral Mucosa. , 1999, , 161-174.		0
904	Erythema Multiforme: A Recent Update. <i>Biomedical and Pharmacology Journal</i> , 2018, 11, 167-170.	0.5	8
905	TEN case due to allopurinol in chronic kidney disease. <i>OrtadoÄŸu TÄ±p Dergisi</i> , 2018, 10, 213-215.	0.1	0
906	Treatment of a Severe Pediatric Lyell Syndrome with Amniotic Membrane: Case Report and Histological Findings. <i>Journal of Tissue Repair and Regeneration</i> , 2018, 1, 12-21.	2.0	1
907	Diagnosis of main rashes in children. <i>Alergologia</i> , 2019, 4, 160.	0.1	0
909	Evaluation of the Effectiveness of Therapy for Stevensâ”Johnson Syndrome and Toxic Epidermal Necrolysis: A Review. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019, 74, 157-166.	0.6	1



#	ARTICLE	IF	CITATIONS
911	Lyell syndrome – considerations upon a clinical case. <i>Pediatru Ro</i> , 2020, 3, 36.	0.0	0
915	Systemic Corticosteroid Therapy for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Vietnam: Clinical Evaluation and Analysis of Serum Cytokines. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 303-308.	0.2	0
916	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. , 0, , .		0
918	Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics. <i>Frontiers in Pharmacology</i> , 2022, 13, 832048.	3.5	17
919	Dermatoses. , 2008, , 343-362.		0
920	A Retrospective Study into Causes and Treatments of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Iranian Patients. <i>Journal of Clinical Care and Skills</i> , 2022, 3, 19-26.	0.1	0
921	Managing the ADR of Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 1039-1046.	2.4	1
922	Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	10
923	Retrospective analysis of cases with Stevens-Johnson syndrome/toxic epidermal necrolysis: A case series of 20 patients. <i>Turk Dermatoloji Dergisi</i> , 2022, 16, 80.	0.1	0
924	Disease severity and status in Stevens-Johnson syndrome and toxic epidermal necrolysis: Key knowledge gaps and research needs. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	0
925	Management of Secondary Lyell Syndrome Due to Anti-Covid Vaccine in a Case, at the Renaissance University Teaching Hospital, Ndjamen (CHAD). <i>Journal of Biosciences and Medicines</i> , 2022, 10, 47-54.	0.2	0
926	STEVENS-JONSON SYNDROME IN CHILDREN - A LOOK AT THE PROBLEM. <i>TavriĖeskij Mediko-biologiĖeskij Vestnik</i> , 2022, 23, 78-85.	0.1	0
927	Đ”Đž ĐŸĐ”ĐċĐĐĐĐ” Đ;ĐĚĐ\$ĐĐ;ĐĐžĐ‡ Đ”Đ†ĐĐ”ĐĐžĐ;ĐċĐ”ĐšĐ” ĐċĐ”Đ”ĐĐ•ĐĐ•ĐĐ Đ†Đ™ĐĐžĐ‡ Đ”Đ†ĐĐ”ĐĐžĐ;ĐċĐĐšĐ” Đ’ĐĐ		
928	Drug-Induced Severe Cutaneous Adverse Reactions, Diagnostics and Management. , 0, , .		1
929	Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	4
930	High Serum Level of TNF-Î± in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 2290-2295.	0.2	0
931	Serum Level of Granulocyte-macrophage Colony-stimulating Factor in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2023, 11, 128-133.	0.2	0
932	Serum Concentrations of Thelper2-derived Cytokines in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2023, 11, 660-664.	0.2	0

#	ARTICLE	IF	CITATIONS
933	Serum Concentrations of Some Thelper1-Derived Cytokines in Generalized Erythema Multiforme. Open Access Macedonian Journal of Medical Sciences, 2023, 11, 665-670.	0.2	0
934	Case report: Generalized bullous fixed drug eruption mimicking epidermal necrolysis. Frontiers in Medicine, 0, 10, .	2.6	1
935	Management of Large Conjunctival Cysts in a Patient with Stevens-Johnson Syndrome: A Case Report and Review of the Literature. Case Reports in Ophthalmology, 0, , 528-534.	0.7	0
936	Clinical Profiles of Japanese Patients with Stevensâ€“Johnson Syndrome/Toxic Epidermal Necrolysis Collected by a Nationwide System from 2006 to 2023. Biological and Pharmaceutical Bulletin, 2024, 47, 88-97.	1.4	0
937	Serum Levels of Interleukin-1 Beta are Decreased in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis at the Time of Hospitalization. Open Access Macedonian Journal of Medical Sciences, 2024, 12, 93-97.	0.2	0